

吴琼 ERIC Q. WU, PH.D.

执行董事

Managing Principal

US Phone: (617) 425 8254  
中国手机: (86) 18601322186  
eric.wu@analysisgroup.com

111 Huntington Avenue  
14<sup>th</sup> Floor  
Boston, MA 02199

吴琼博士是一名在医药经济、医疗大数据、医疗产品产出以及相关的医疗临床与市场研究领域资深的卫生经济学家与统计学家。他的研究项目与服务的客户涵盖北美、欧洲、亚洲、南美洲和其它新兴市场的医药、医疗仪器公司，医疗保险、医疗服务机构、和政府机构。他领导的研究与咨询项目建立在科学分析方法与医疗大数据基础之上，主要包括医疗领域的临床、经济、产出、政策研究以及科学数据开发与使用策略的制定；不同治疗方法间的比较有效性研究；医院及其它医疗机构合理化病人管理与治疗决策的临床与经济分析；医疗保险政策与决策分析；为治疗指导方针的制定进行经济建模；为医疗产品申报，药品目录及药品报销目录的制定与修改提供临床与经济的科学数据；针对医生、医疗机构、保险机构的病人个性化治疗方案的制定与执行工具的开发；临床实验的设计与分析；阶段治疗方案设计；仿制药和生物制剂的使用合理性分析；早期评估新技术新产品价值与前景；医药市场分析；研究药物与其它治疗方法直接以及间接导致的医疗资源使用情况和费用、病人生活质量的改变、工作效益损失；药物的实际使用情况分析；疾病的发病率分析及其它流行病学研究；药物安全性研究。他还致力于开发医药领域新的研究和统计方法、以及医疗大数据及相应研究方法与使用工具的开发。吴琼博士是中国注册医师协会医药经济中心的顾问委员会成员，也是《药物经济学》（Pharmacoeconomics）中国专刊的主编。

## 工作经历

2002-Present  
安诺析思国际咨询公司  
Analysis Group, Inc.  
Boston, MA

## 教育背景

1998-2002  
美国南加州大学药物经济与政策学博士  
Ph.D., University of Southern California  
Department of Pharmaceutical Economics and Policy  
School of Pharmacy

2001-2002  
美国南加州大学医疗政策法规硕士  
M.Sc., University of Southern California  
Master's Program in Regulatory Science (Regulation, Law, and  
Management in Health Care and Pharmaceutical Industry)  
School of Pharmacy

1998-2000                    美国南加州大学经济学硕士  
**M.A., University of Southern California**  
Department of Economics  
Successfully Completed the Ph.D. Core Theory Examinations for the  
Department of Economics

1993-1997                    北京大学生物化学与分子生物学学士  
**B.S., Peking University, Beijing, China**  
Biochemistry and Molecular Biology Department  
School of Life Sciences

#### 北大校友社区

北京大学校友会理事  
北京大学北美新英格兰校友会理事  
北京大学企业家俱乐部理事

## PUBLICATIONS AND PRESENTATIONS

### *Journal Articles (Peer-reviewed Journals)*

1. Xie JHY, Li N, Lin P, Ohashi E, Koo V, Wu EQ. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Accepted for publication by *Experimental Hematology & Oncology*. To be published in December, 2015.
2. Lin PL, Hao Y, Xia J, Li N, Zhong Y, Zhou Z, Signorovitch J, Wu EQ. Physician Experiences and Preferences in the Treatment of HR+/HER2- Metastatic Breast Cancer in the US: A Physician Survey. Accepted Oct 12, 2015 for publication in *Cancer Medicine*.
3. Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA. Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. *Diabetes Therapy* 2015 Sep; 6(3): 339-355. doi: 10.1007/s13300-015-0122-2
4. Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, **Wu EQ**. Real-World Effectiveness of Everolimus-based Therapy versus Endocrine Monotherapy and Chemotherapy in Patients of HR+/HER2 – Breast Cancer with Liver Metastasis. Accepted for publication in *Expert Opinion on Pharmacotherapy*. Manuscript accepted July 2015 for publication.
5. Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, **Wu EQ**. Clinical Outcomes with First-Line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2 – Metastatic Breast Cancer. *Breast Cancer* (Auckl). 2015 (in press)
6. Shiozawa A, Cloutier M, Heroux J, Guerin A, **Wu EQ**, Jackson R. Real-World Treatment Patterns of Gout Patients Treated with Colchicine or Other Common Treatments for Gout in Acute Care Settings: A Retrospective Chart Review Study. *Current Medical Research & Opinion*. 2015 Oct:1-34.
7. Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, **Wu EQ**. Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection. *JAMA Oncology*. 2015 Oct.

8. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, **Wu EQ**. Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. *International Journal of Breast Cancer*. 2015;2015:240750. doi: 10.1155/2015/240750. Epub 2015 May 20.
9. Li N, Hao Y, Xie J, Lin PL, Ohashi E, Koo V, **Wu EQ**, Yardley DA. Comparative Effectiveness of Everolimus-based Therapy versus Chemotherapies among Post-menopausal Women with HR+/HER2- Metastatic Breast Cancer: A US Chart Review Study. *International Journal of Breast Cancer*, 2015 May 13:1-9. [Epub ahead of print]
10. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, **Wu EQ**. Comparative Effectiveness of Everolimus-based Therapy versus Endocrine Monotherapy among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer: A Retrospective Chart Review in Community Oncology Practices in the US. *Current Medical Research & Opinion*. 2015 June (doi: 10.1185/03007995.2015.1021906)
11. Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, **Wu EQ**, Rogerio J. Comparative Effectiveness of Everolimus-based Therapy versus Fulvestrant Monotherapy in Post-menopausal Women with HR+/HER2- Metastatic Breast Cancer. *J Comp Eff Res*, 2015; Epub ahead of print
12. Gibney GT, Gauthier G, Ayas C, Galebach P, **Wu E**, Abhyankar S, Reyes C, Guérin A, Yeun MY. Treatment Patterns and Outcomes in BRAF V600E Mutant Melanoma Patients with Brain Metastases Receiving Vemurafenib in the Real-World Setting. *Cancer Medicine*
13. Guérin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, **Wu EQ**, Wakelee H. ALK Rearrangement Testing and Treatment Patterns for Patients with ALK-positive Non-Small Cell Lung Cancer. *Cancer Epidemiology*. 2015 June. pii: S1877-7821(15)00087-9. doi: 0.1016/j.canep.2015.04.005.
14. Bonthapally V, **Wu E**, Macalalad A, Yang H, Shonukan O, Lio Y, Chi A, Huebner D. Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Post-autologous Transplant: Meta-analysis versus Historical Data. *Current Medical Research and Opinion*. 2015 May 31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.
15. Armstrong AW, Guérin A, Sundaram M, **Wu EQ**, Faust ES, Ionescu-Ittu R, Mulani P. Psoriasis and Risk of Diabetes-associated Microvascular and Macrovascular Complications. *Journal of American Academy of Dermatology*. 2015 June. pii: S0190-9622(15)01303-1. doi: 10.1016/j.jaad.2015.02.1095
16. Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, **Wu EQ**, Shonukan O, Bonthapally V. The Epidemiology and Targeted Therapies for Relapsed and Refractory CD30+ Lymphomas. *Current Medical Research and Opinion*. 2015 Mar;31(3):537-45. Epub 2015 Feb 9.
17. Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, **Wu EQ**. Brain Metastases in Patients with ALK+ Non-small Cell Lung Cancer: Clinical Symptoms, Treatment Patterns and Economic Burden. *JME* 2015 Jan 7.
18. Guérin A, Sasane M, Gauthier G, Keir C, Zhdanava M, **Wu EQ**. The Economic Burden of Gastrointestinal Stromal Tumor (GIST) Recurrence in Patients who have Received Adjuvant Imatinib. *JME* 2014 Dec 5.
19. Langer C, Ravelo A, Hazard SJ, Guérin A, Ionescu-Ittu R, Latremouille-Viau, **Wu EQ**, Ramalingam S. Comparison of Survival and Hospitalization Rates between Medicare Patients with Advanced NSCLC Treated with Bevacizumab-carboplatin-paclitaxel and Carboplatin- paclitaxel: A Retrospective Cohort Study. *Lung Cancer Journal*. 2014 Dec.

20. Mody R, Guérin A, Fok B, Lasch KL, Zhou Z, **Wu EQ**, Zhou W, Talley NJ. Prevalence and Risk of Developing Comorbid Conditions in Patients with Chronic Constipation. *Current Medical Research and Opinion*. 2014 Dec.
21. Fuldeore M, Yang H, Du EX, Soliman AM, **Wu EQ**, Winkel C. Healthcare Utilization and Costs in Women Diagnosed with Endometriosis before and after Diagnosis: a Longitudinal Analysis of Claims Databases. *Fertil Steril*. 2014 Nov 15.
22. Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, **Wu EQ**, Chen L, DeAngelo DJ. One-year and Long-term Molecular Response to Nilotinib and Dasatinib for Newly Diagnosed Chronic Myeloid Leukemia: a matching-adjusted indirect comparison. *Current Medical Research and Opinion*. 2014 Nov 7.
23. Macalalad AR, Hao Y, Lin PL, Signorovitch JE, **Wu EQ**, Ohashi E, Zhou Z, Kelley C. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). *Current Medical Research and Opinion*. 2014 Nov 7:1-11.
24. Loftus E, Skup M, Ozbay BA, **Wu EQ**, Guérin A, Chao J, Mulani P. The impact of moderate-to-severe crohn's disease on employees' salary growth. *Inflammatory Bowel Diseases*. 2014 Oct.
25. Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, **Wu EQ**. Cost-utility of hub-and-spoke telestroke networks from the societal perspective. *American Journal of Managed Care*. 2014.
26. Hurvitz S, Guérin A, Brammer M, Guardino E, Zhong ZY, Latremouille Viau D, **Wu EQ**, Lalla D. Investigation of adverse-event related costs in patients with metastatic breast cancer in a real-world setting. *The Oncologist*. 2014.
27. Guérin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, **Wu EQ**. Impact of Low-Grade Adverse Events on Health-Related Quality of Life In Adult Patients Receiving Imatinib or Nilotinib for Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase. *Current Medical Research and Opinion*. 2014 Aug 5:1-12.
28. Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, deLeon A, Erder MH, **Wu EQ**. Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention deficit/hyperactivity disorder (ADHD) during 2009. *Journal of Child and Adolescent Psychopharmacology*; 24(5) 2014:260-8.
29. Guérin A, Chen L, Dea, K, **Wu EQ**, Goldberg SL. Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. *Current Medical Research Opinion*. 2014 Jul;30(7):1345-52. Epub 2014 Mar 21.
30. Bron M, Guérin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, **Wu EQ**. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. *Journal of Medical Economics*. 2014 Jun 24:1-12.
31. Guérin A, Carson R, Lewis B, Yin D, Kaminsky M, **Wu EQ**. The economic burden of treatment failure among patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a medicaid population. *Journal of Medical Economics*. 2014 Aug;17(8):577-86. Epub 2014 May 28.
32. Conley AP, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir CH, **Wu EQ**. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients – a chart extract-based approach. *Journal of Gastrointestinal Cancer*. 2014 [in progress] Epub: 2014 May 22.

33. Guérin A, Mody R, Fok B, Lasch KL, Zhou Z, **Wu EQ**, Zhou W, Talley NJ. Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. *Alimentary Pharmacology & Therapeutics*. 2014 Jul;40(1):83-92. Epub 2014 May 15.
34. Guérin A, Lalla D, Gauthier G, Styles A, **Wu EQ**, Masaquel A, Brammer MG. Comparison of Treatment Patterns and Economic Outcomes in Metastatic Breast Cancer Patients Initiated on Trastuzumab versus Lapatinib: A Retrospective Analysis. *SpringerPlus*. 2014 May 8;3:236.
35. Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, **Wu EQ**. Real-World Adherence and Persistence Associated with Nebivolol or Hydrochlorothiazide as Add-On Treatment for Hypertension. *Current Medical Research and Opinion*. 2014 Apr; 30(4):637-43. Epub 2013 Nov 26.
36. Liang W, Xie J, Fu H, **Wu EQ**. The Role of Health Economics and Outcomes Research in Health Care Reform in China. *Pharmacoeconomics*. 2014 Mar;32(3):231-4.
37. Signorovitch J, Ayyagari R, Reichmann WM, **Wu EQ**, Chen L. Major Molecular Response During the First Year of Dasatinib, Imatinib or Nilotinib Treatment for Newly Diagnosed Chronic Myeloid Leukemia: A Network Meta-Analysis. *Cancer Treatment Reviews*. 2014 Mar; 40(2):285-92. Epub 2013 Sep 17.
38. **Wu EQ**, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y. Treatment, Monitoring, and Economic Outcomes of Venous Thromboembolism among Hospitalized Patients in China. *Pharmacoeconomics*. 2014 Mar; 32(3):305-13.
39. Guérin A, Chen L, Liu N, Dea K, **Wu EQ**, Goldberg S. Economic Benefits of Adequate Molecular Monitoring in Patients with Chronic Myelogenous Leukemia. *Journal of Medical Economics*. 2014 Feb; 17(2):89-98. Epub 2013 Nov 26.
40. Yang H, Chaudhari P; Zhou Z; **Wu EQ**, Pate C, Horn D. Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States. *Applied Health Economics and Health Policy*. 2014 Feb; 12(1):85-93.
41. Guérin A, **Wu EQ**, Bollu VK, Williams D, Guo A, Ponce de Leon D, Quintas- Cardama A. The Economic Burden Of Pleural Effusions in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors. *Journal of Medical Economics*. 2013; 16(1):125-33. Epub 2012 Jun 6.
42. Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, **Wu EQ**, Santos E. Comparison of Discontinuation, Health Care Resource Utilization (Hru), and Costs between Metastatic Breast Cancer (Mbc) Patients (Pts) who received Trastuzumab (T) in an Office Clinic versus Outpatient Hospital Setting. *Journal of Clinical Oncology*. 31, 2013.
43. Kan H, Guérin A, Kaminsky MS, Yu AP, **Wu EQ**, Denio A, Jhingran P, Narayanan S, Molta C. A Longitudinal Analysis of Costs Associated With Change in Disease Activity in Systemic Lupus Erythematosus. *Journal of Medical Economics*. 2013; 16(6):793-800. Epub 2013 May 15.
44. Ray S, Bonthapally V, Holen K, Gauthier G, **Wu E**, Cloutier, M, Guérin A. Economic Burden of Dermatologic Adverse Drug Reactions in the Treatment of Colorectal, Non-Small Cell Lung, and Head and Neck Cancers with Epidermal Growth Factor Receptor Inhibitors. *Journal of Medical Economics*. 2013; 16(2):221-30. Epub 2012 Nov 27.
45. Xie J, Diener M, De G, Yang H, **Wu EQ**, Namjoshi M. Budget Impact Analysis of Everolimus for the Treatment of Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative (Her2-) Advanced Breast Cancer in the United States. *Journal of Medical Economics*. 2013; 16(2): 278-88. Epub 2012 Dec 5.

46. Deangelo DJ, Chen L, Guérin A, Styles A, Giguere-Duval P, **Wu EQ**. Impact of Timely Switching from Imatinib to a Second-Generation Tyrosine Kinase Inhibitor after 12-month Complete Cytogenetic Response Failure: A Chart Review Analysis. *Clinical Lymphoma Myeloma and Leukemia*. 2013 Dec 17.
47. Demaerschalk BM1, Switzer JA, Xie J, Fan L, Villa KF, **Wu EQ**. Cost Utility of Hub-and-Spoke Telestroke Networks from Societal Perspective. *American Journal of Managed Care*. 2013 Dec; 19(12):976-85.
48. Setyawan J1, Guérin A, Hodgkins P, Gauthier G, Cloutier M, **Wu EQ**, Erder MH. Treatment Persistence in Attention Deficit/Hyperactivity Disorder: A Retrospective Analysis of Patients Initiated on Lisdexamfetamine vs Other Medications. *Journal of Medical Economics*. 2013 Nov; 16(11):1275-89. Epub 2013 Sep 19.
49. Sikirica V, Findling R, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, **Wu EQ**. Comparative Efficacy of Guanfacine Extended Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology. *CNS Drugs*. 2013 Nov; 27(11):943-53.
50. Macaulay D, Sun SX, Sorg RA, Yan SY, De G, **Wu EQ**, Simonelli PF. Development and Validation of a Claims-based Prediction Model for COPD Severity. *Respiratory Medicine*. 2013 Oct; 107(10):1568-77. Epub 2013 Jun 25.
51. Sawicki G, Ayyagari R, Zhang J, Signorovitch J, Fan L, Swallow E, Latremouille-Viau D, **Wu E**, Shi L. A Pulmonary Exacerbation Risk Score among Cystic Fibrosis Patients not Receiving Recommended Care. *Pediatric Pulmonology*. 2013 Oct; 48(10):954-61. Epub 2012 Dec 19.
52. Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, **Wu EQ**, Erder MH. Comparison of Therapy Augmentation and Deviation Rates from the Recommended Once-Daily Dosing Regimen Between Ldx and Commonly Prescribed Long-Acting Stimulants for the Treatment of ADHD in Youth and Adults. *Journal of Medical Economics*. 2013 Oct;16(10):1203-15. Epub 2013 Aug 23.
53. Goldberg SL, Chen L, Guérin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, **Wu EQ**. Association Between Molecular Monitoring and Long Term Outcomes in Chronic Myelogenous Leukemia Patients Treated With First Line Imatinib. *Current Medical Research & Opinion*. 2013 Sep; 29(9):1075-82. Epub 2013 Jun 21.
54. Shi L, Ye X, Lu M, **Wu EQ**, Sharma H, Thomason D, Fonseca VA. Clinical and Economic Benefits Associated with the Achievement of Both Hba1c and LDL Cholesterol Goals in Veterans with Type 2 Diabetes. *Diabetes Care*. 2013 Oct; 36(10):3297-304. Epub 2013 Jun 25.
55. Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, **Wu EQ**, Liu J, Yang H, Shi L. Study of Imatinib Treatment Patterns and Outcomes among US Veteran Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia. *Journal of Oncology Practice*. 2013 Sep; 9(5):e212-9. Epub 2013 May 28.
56. Krishnan E, Akhras KS, Sharma H, Marynchenko M, **Wu EQ**, Tawk R, Liu J, Shi L. Relative and Attributable Diabetes Risk Associated with Hyperuricemia in US Veterans with Gout. *Quarterly Journal of Medicine*. 2013 Aug; 106(8):721-9. Epub 2013 Apr 24.
57. Guérin A, Lin J, Jhaveri M, **Wu EQ**, Yu AP, Cloutier M, Gauthier G, Alspert JS. Outcomes in Atrial Fibrillation Patients on Combined Warfarin and Antiarrhythmic Therapy. *International Journal of Cardiology*. 2013 Jul 31; 167(2):564-9. Epub 2012 Feb 14.

58. Krishnan E, Akhras KS, Sharma H, Marynchenko M, **Wu EQ**, Tawk RH, Liu J, Shi L. Serum urate and Incidence of Kidney Disease among Veterans with Gout. *Journal of Rheumatology*. 2013 Jul; 40(7):1166-72. Epub 2013 May 15.
59. Setyawan J., Hodgkins P, Guérin A, Gauthier G, Cloutier M, **Wu EQ**, Erder HM. Comparing Treatment Adherence of Lisdexamfetamine and other Medications for the Treatment of Attention Deficit/Hyperactivity Disorder: A Retrospective Analysis. *Journal of Medical Economics*. 2013 Jul 16(7):962-75. Epub 2013 Jun 7.
60. Conley AP, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir CH and **Wu EQ**. Comparison of the Long-Term Risk of Recurrence and other Clinical Outcomes in Gist Patients Receiving Imatinib as Adjuvant Therapy: A Retrospective Chart Extract-Based Approach. *Journal of Gastrointestinal Cancer*. 2013 Jun; 44(2):190-8.
61. Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, **Wu EQ**, Sikirica V. Authors' reply to Alatorre et al.: "Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison". *Applied Health Economics and Health Policy*. 2013 Jun; 11(3):307.
62. Griffin JD, Guérin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, **Wu EQ**. Comparing Nilotinib with Dasatinib as Second-Line Therapies in Patients with Chronic Myelogenous Leukemia Resistant or Intolerant to Imatinib - A Retrospective Chart Review Analysis. *Current Medical Research Opinion*. 2013 Jun; 29(6):623-31. Epub 2013 Apr 8.
63. Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder MH, Dammerman R, Robertson B, **Wu EQ**. Impact of Atypical Antipsychotic use among Adolescents with Attention Deficit/Hyperactivity Disorder. *American Journal of Managed Care*. 2014 Sept; 20(9):711-21.
64. Signorovitch JE, Macaulay D, Diener M, Yan Y, **Wu EQ**, Gruenberger JB, Frier BM. Hypoglycaemia and Accident Risk in People with Type 2 Diabetes Mellitus Treated with Non-Insulin Antidiabetes Drugs. *Diabetes, Obesity and Metabolism*. 2013 Apr; 15(4):335-41. Epub 2012 Nov 22.
65. Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, **Wu EQ**. Cost-effectiveness of Hub-And-Spoke Telestroke Networks for the Management of Acute Ischemic Stroke from the Hospitals' Perspectives. *Circulation: Cardiovascular Quality and Outcomes*. 2013 Jan 1; 6(1):18-26. Epub 2012 Dec 4.
66. Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins PS, **Wu EQ**. Identifying Patient Subgroups who Benefit Most from a Treatment — Using Administrative Claims Data to Uncover Treatment Heterogeneity. *Journal of Medical Economics*. 2012; 15(6):1078-87. Epub 2012 Jun 14.
67. Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, **Wu EQ**. Treatment Patterns and Economic Burden of Metastatic and Recurrent Locally-Advanced Head and Neck Cancer Patients. *Journal of Medical Economics*. 2012; 15(4):786-95. Epub 2012 Apr 20.
68. Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, **Wu EQ**. Comparative Treatment Patterns, Resource Utilization, and Costs in Stimulant-Treated Children with ADHD who require Subsequent Pharmacotherapy with Atypical Antipsychotics versus Non-Antipsychotics. *Journal of Managed Care Pharmacy*. 2012 Nov-Dec; 18(9):676-89.
69. Chen L, Guérin A, Xie J, **Wu EQ**, Yu AP, Ericson SG, Jabbour E. Monitoring and Switching Patterns of Patients with Chronic Myeloid Leukemia Treated with Imatinib in Community Settings: A Chart Review Analysis. *Current Medical Research and Opinion*. 2012 Nov; 28(11):1831-9. Epub 2012 Nov 5.

70. Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins PS, Lu M, **Wu EQ**, Sikirica V. Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention- Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison. *Applied Health Economics and Health Policy*. 2012 Nov 1; 10(6):381-395(15).
71. **Wu EQ**, Forsythe A, Guérin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. *American Journal of Therapeutics*. 2012 Nov; 19(6):e157-66.
72. Kimball AB, **Wu EQ**, Guérin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM. Risks of Developing Psychiatric Disorders in Pediatric Patients with Psoriasis. *Journal of the American Academy of Dermatology*. 2012 Oct; 67(4): 651-57. Epub 2012 Jan 13.
73. **Wu EQ**, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes Associated with Post-Discharge Insulin Continuity in Us Patients with Type 2 Diabetes Mellitus Initiating Insulin in the Hospital. *Hospital Practice (1995)*. 2012 Oct; 40(4):40-8.
74. Signorovitch JE, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, **Wu EQ**. R1 Matching-adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research. *Value in Health*. 2012 Sep; 15(6):940-7.
75. Sikirica V, Erder MH, Xie J, Macaulay M, Diener M, Hodgkins P, **Wu EQ**. Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents. *PharmacoEconomics*. 2012 Aug 1; 30(8):1-15.
76. Xie J, Diener M, Sorg R, **Wu EQ**, Namjoshi M. Cost-effectiveness of Denosumab compared with Zoledronic Acid in Patients with Breast Cancer and Bone Metastases. *Clinical Breast Cancer*. 2012 Aug; 12(4):247-58. Epub 2012 Jun 12.
77. Guérin A, Chen L, **Wu EQ**, Ponce de Leon D, Griffin JD. A Retrospective Analysis of Therapy Adherence in Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukemia Receiving Nilotinib or Dasatinib in a Real-World Setting. *Current Medical Research and Opinion*. 2012 Jul; 28(7): 1155-62. Epub 2012 Jun 28.
78. Liu Y, **Wu EQ**, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P. Cost per Responder associated with Biologic Therapies for Crohn's Disease, Psoriasis, and Rheumatoid Arthritis. *Advances in Therapy*. 2012 Jul; 29(7): 620-34. Epub 2012 Jul 27.
79. **Wu E**, Chen L. Re: Ulcickas Yood M, Oliveira SA, Cziraky M et al. Adherence to Treatment with Second-Line Therapies, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia. *Current Medical Research and Opinion*. 2012 Jul; 28(7):1164 author reply 1164-5. Epub 2012 Jul 2.
80. **Wu EQ**, Hodgkins PS, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH. Cost-effectiveness of Pharmacotherapies for Attention-Deficit Hyperactivity Disorder: Results from a Systematic Literature Review. *CNS Drugs*. 2012 Jul 1; 26(7):581-600.
81. Signorovitch JE, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, **Wu EQ**. Comparative Effectiveness Research using Matching-Adjusted Indirect Comparison: An Application to Treatment with Guanfacine Extended Release or Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder. *Pharmacoepidemiology Drug Safety*. 2012 May; 21 Supplement 2:130-7.

82. Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, **Wu EQ**, Blum SI, Ramasamy A, Chen S. Persistence with Nebivolol in the Treatment of Hypertension: A Retrospective Claims Analysis. *Current Medical Research and Opinion*. 2012 Apr; 28(4):591-9. Epub 2012 Mar 16.
83. Xie Y, Shi L, Xiong X, **Wu EQ**, Veasley C, Dade C. Economic Burden and Quality of Life of Vulvodynia in the United States. *Current Medical Research and Opinion*. 2012 April; 28(4): 601-608. Epub 2012 Mar 20.
84. **Wu EQ**, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T. Outcomes associated with Insulin Therapy Disruption after Hospital Discharge among US Patients with Type 2 Diabetes who had Used Insulin Prior to and During Hospitalization. *Endocrine Practice*. 2012 Mar 22:1-27.
85. Xie J, Namjoshi M, **Wu EQ**, Parikh K, Diener M, Yu AP, Guo A, Culver KW. Economic Evaluation of Denosumab compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. *Journal of Managed Care Pharmacy*. 2012 Jan-Feb; 18(1):74-5.
86. Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, **Wu EQ**, Shi L. Reduced Mortality in Cystic Fibrosis Patients Treated with Tobramycin Inhalation Solution. *Pediatric Pulmonology*. 2012 Jan; 47(1):44-52. Epub 2011 Aug 3.
87. **Wu EQ**, Ben-Hamadi R, Lu M, Beaulieu N, Yu PA, Erder MH. Treatment Persistence & Health Care Costs of Adult MDD Patients treated with Escitalopram vs. Citalopram in a Medicaid Population. *Managed Care*. 2012 Jan; 21(1):49-58.
88. Bron M, Marynchenko M, Yang H, Yu AP, **Wu EQ**. Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs. *Postgraduate Medicine*. Jan 2012:124(1), 124-132.
89. Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, **Wu EQ**. Compliance, Persistence, Healthcare Resource Use, and Treatment Costs associated with Aliskiren Plus Arb versus Ace Inhibitor Plus Arb Combination Therapy: In US Patients with Hypertension. *American Journal of Cardiovascular Drugs*. 2011; 11(1):21-32.
90. Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, **Wu EQ**, Ben-Hamadi R, Blum S, Erder MH, Bose A. Economic Outcomes of Switching to another Generic Ssri, Escitalopram, or an SNRI among MDDvPatients treated with Generic SSRI Therapy. *American Journal of Pharmacy Benefits*. 2011; 3(6):e111-e120 (Web Exclusive article).
91. Signorovitch JE, **Wu EQ**, Swallow E, Kantor E, Fan L, Gruenberger J-B. Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes: A Matching-Adjusted Indirect Comparison of Randomized Trials. *Clinical Drug Investigation*. 2011; 31(9):665-74.
92. Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, **Wu EQ**. Cost-effectiveness Analysis of Roflumilast/Tiotropium Therapy versus Tiotropium Monotherapy for Treating Severe-to-Very Severe COPD. *Journal of Medical Economics*. 2011; 14 (6): 805–815. Epub 2011 Oct 12.
93. Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, **Wu EQ**, Fan CP, Yu AP. Copayment Level, Treatment Persistence, and Health Care Utilization In Hypertension Patients Treated with Single-Pill Combination Therapy. *Journal of Medical Economics*. 2011; 14(3): 267-78. Epub 2011 Mar 30.
94. Yang H, Yu AP, **Wu EQ**, Yim YM, Yu E. Healthcare Costs Associated with Bevacizumab and Cetuximab in Second-Line Treatment of Metastatic Colorectal Cancer. *Journal of Medical Economics*. 2011; 14(5):542-52. Epub 2011 Jul 6.

95. Yu AP, Ben-Hamadi R, **Wu EQ**, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH. Impact of Initiation Timing Of SSIR Or SNRI on Depressed Adolescent Healthcare Utilization and Costs. *Journal of Medical Economics*. 2011; 14(4):508-15. Epub 2011 Jun 21.
96. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Mocarski M, Blum S, Setyawan J. Therapy Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease: Multiple versus Single Long-Acting Maintenance Inhalers. *Journal of Medical Economics*. 2011; 14(4):486-96. Epub 2011 Jun 16.
97. Yu AP, Yang H, **Wu EQ**, Juliana Setyawan J, Mocarski M, Blum S. Incremental Third-Party Costs associated with COPD Exacerbations: A Retrospective Claims Analysis. *Journal of Medical Economics*. 2011; 14(3): 315-23. Epub 2011 Apr 18.
98. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, **Wu EQ**, Mocarski M, Blum SI, Setyawan J. Clinical and Economic Outcomes of Multiple versus Single Long-Acting Inhalers in COPD. *Respiratory Medicine*. 2011 Dec; 105(12):1861-71. Epub 2011 Jul 31.
99. Xie J, Namjoshi M, **Wu EQ**, Parikh K, Diener M, Yu AP, Guo A, Culver KW. Economic Evaluation of Denosumab compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. *Journal of Managed Care Pharmacy*. 2011 Oct; 17(8):621-43.
100. Loftus EV, Guérin A, Yu AP, **Wu EQ**, Yang M, Chao J, Mulani PM. Increased Risks Of Developing Anxiety and Depression in Young Patients with Crohn's Disease. *American Journal of Gastroenterology*. 2011 Sep; 106(9):1670-7. Epub 2011 May 3.
101. **Wu EQ**, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N. Comparison of Skeletal Complications and Treatment Patterns associated with Early versus Delayed Zoledronic Acid Therapy in Multiple Myeloma. *Clinical Lymphoma, Myeloma & Leukemia*. 2011 Aug; 11(4):326-35. Epub 2011 May 6.
102. Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, **Wu EQ**, Dworak H, Haim Erder M. Remission Of Major Depressive Disorder without Adverse Events: A Comparison of Escitalopram Versus Serotonin Norepinephrine Reuptake Inhibitors. *Current Medical Research and Opinion*. 2011 Jun; 27(6):1089-96. Epub 2011 Mar 28.
103. Signorovitch JE, **Wu EQ**, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. Comparative Efficacy of Nilotinib and Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia: A Matching-Adjusted Indirect Comparison of Randomized Trials. *Current Medical Research and Opinion*. 2011 Jun; 27(6):1263-71. Epub 2011 Apr 28.
104. **Wu EQ**, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH. Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder (April). *Annals of Pharmacotherapy*. 2011 Apr; 45(4):441-51. Epub 2011 Mar 17.
105. Velde NV, **Wu EQ**, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L. The Benefits of Timely Intervention with Zoledronic Acid in Patients with Metastatic Prostate Cancer to Bones: A Retrospective Study of the US Veterans Affairs population. *Prostate Cancer and Prostatic Diseases*. 2011 Mar; 14(1):79-84. Epub 2010 Dec 21.
106. Kimball AB, Bensimon AG, Guérin A, Yu AP, **Wu EQ**, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities: Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase Iii Trial. *American Journal of Clinical Dermatology*. 2011 Feb 1;12 (1):51-62.

107. Kimball AB, Guérin A, Tsaneva M, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Economic Burden Of Comorbidities in Patients with Psoriasis is Substantial. *Journal of the European Academy of Dermatology and Venereology*. 2011 Feb; 25(2):157-163. Epub 2010 Jun 17.
108. Loftus EV Jr., Johnson SJ, Wang ST, **Wu EQ**, Mulani PM, Chao J. Risk-Benefit Analysis of Adalimumab versus Traditional Non-Biologic Therapies for Patients with Crohn's Disease. *Inflammatory Bowel Diseases*. 2011 Jan; 17 (1): 127-40.
109. Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, **Wu EQ**. Achieving Glycemic Goal with Initial versus Sequential Combination Therapy using Metformin and Pioglitazone in Type 2 Diabetes Mellitus. *Current Medical Research and Opinion*. 2011 Jan; 27 (1):189-95. Epub 2010 Dec 9.
110. Mease PJ, Signorovitch J, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Impact of Adalimumab on Symptoms of Psoriatic Arthritis in Patients With Moderate to Severe Psoriasis: A Pooled Analysis Of Randomized Clinical Trials. *Dermatology*. 2010; 220(1):1-7. Epub 2009 Nov 19.
111. Saurat JH, Guérin A, Yu AP, Latremouille-Viau D, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice. *Dermatology*. 2010; 220(2):128-37. Epub 2010 Feb 3.
112. Signorovitch JE, **Wu EQ**, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. Comparative Effectiveness Without Head-to-Head Trials: A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab Or Etanercept. *PharmacoEconomics*. 2010; 28(10):935-45.
113. Yu AP, Xie J, Bensimon A, Parikh K, **Wu EQ**, Ben-Hamadi R, Blum S, Erder HM. Economic Consequence of Switching to Citalopram after its Generic Entry for Adult Patients with Major Depressive Disorder (Mdd) Treated with Escitalopram: A 6-Month Retrospective Study. *Journal of Medical Economics*. 2010; 13(4):599-609. Epub 2010 Sep 29.
114. Reich K, Signorovitch J, Ramakrishnan K, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Benefit-risk Analysis of Adalimumab versus Methotrexate and Placebo in the Treatment of Moderate to Severe Psoriasis: Comparison Of Adverse Event-Free Response Days in the CHAMPION trial. *Journal of the American Academy of Dermatology*. 2010 Dec; 63(6):1011-8. Epub 2010 Oct 8.
115. **Wu EQ**, Guérin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective Real-World Comparison of Medical Visits, Costs, and Adherence between Nilotinib and Dasatinib in Chronic Myeloid Leukemia. *Current Medical Research and Opinion*. 2010 Dec; 26(12):2861-9. Epub 2010 Nov 9.
116. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, **Wu EQ**, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. The CHOICE trial: Adalimumab Demonstrates Safety, Fistula Healing, Improved Quality of Life and Increased Work Productivity in Patients with Crohn's Disease who Failed Prior Infliximab Therapy. *Alimentary Pharmacology & Therapeutics*. 2010 Nov; 32(10):1228-39. Epub 2010 Sep 28.
117. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Setyawan J, Dembiski M, Blum SI. Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) treated with multiple vs. Single long-acting inhalers. *Chest*. 2010 Oct; 138(4):482A.
118. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Setyawan J, Dembiski M, Blum SI. Risk of Exacerbations among Patients with Chronic Obstructive Pulmonary Disease (COPD) treated with Multiple vs. Single Long-acting Inhalers. *Chest*. 2010 Oct; 138(4):478A.

119. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Xie J, **Wu EQ**, Setyawan J, Dembiski M, Blum SI. Resource Utilization and Costs in Patients with Chronic Obstructive Pulmonary Disease (COPD) treated with Multiple vs. Single Long-acting Inhalers. *Chest*. 2010 Oct; 138(4):485A
120. Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, **Wu EQ**. Chart Review of Patients on Valsartan-based Single-pill Combinations vs. Arb-based free combinations for bp goal achievement. *Current Medical Research and Opinion*. 2010 Sep; 26(9):2203-12.
121. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, **Wu EQ**, Bensimon AG. Evaluation of Compliance and Health Care Utilization in Patients Treated with Single Pill vs. Free Combination Antihypertensives. *Current Medical Research and Opinion*. 2010 Sep; 26(9):2065-76.
122. **Wu EQ**, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A. Healthcare Utilization and Costs incurred by Patients with Major Depression after being switched from Escitalopram to another SSRI for Non-medical Reasons. *Journal of Medical Economics*. 2010 Jun; 13(2):314-23.
123. Guérin A, Bollu V, Guo A, **Wu EQ**, Yu AP, Sirulnik LA, Griffin JD. Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short- and long-term negative impacts on healthcare resource utilization and costs. *Value in Health*. 2010 May; 13(3):A32.
124. Menter A, Augustin M, Signorovitch J, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani P. The effect of Adalimumab on Reducing Depression Symptoms in Patients with Moderate to Severe Psoriasis: A Randomized Clinical Trial. *Journal of the American Academy of Dermatology*. 2010 May; 62(5):812-8. Epub 2010 Mar 9.
125. Cohen RD, Yu AP, **Wu EQ**, Xie J, Mulani PM, Chao J. Systematic Review: The Costs of Ulcerative Colitis in Western Countries. *Aliment Pharmacology & Therapeutics*. 2010 Apr; 31(7):693-707. Epub 2010 Jan 11.
126. Signorovitch J, Zhang J, **Wu EQ**, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH. Economic Impact of switching from Valsartan to other Angiotensin Receptor Blockers in Patients with Hypertension. *Current Medical Research and Opinion*. 2010 Apr; 26(4):849-60.
127. Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, **Wu EQ**. Diabetes-related Costs associated with Hypoglycemia in Type 2 Diabetes Mellitus Patients Initiated on Oral Antidiabetic Drugs. *Journal of Managed Care Pharmacy*. 2010 Mar; 16(2):147.
128. **Wu EQ**, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Healthcare Resource Utilization and Costs associated with Non-Adherence to Imatinib Treatment in Chronic Myeloid Leukemia Patients. *Current Medical Research and Opinion*. 2010 Jan; 26(1):61-9.
129. Birnbaum H, Greenberg P, Tang J, Hsieh M, **Wu EQ**, Amand C, Ben-Hamadi R. Antidepressant Treatment Patterns and Costs among US Employees. *Journal of Medical Economics*. 2009; 12(1): 36-45.
130. Chey WD, Mody RR, **Wu EQ**, Chen L, Kothari S, Persson B, Beaulieu N, Lu M. Treatment Patterns and Symptom Control in Patients with GERD: US Community-based Survey. *Current Medical Research and Opinion*. 2009; 25(8):1869-78.
131. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, **Wu EQ**, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-severe Crohn's Disease: Results from the CHARM Trial. *American Journal of Gastroenterology*. 2009; 104(5):1170-9. Epub 2009 Apr 7.

132. Nelson SP, Kothari S, **Wu EQ**, Beaulieu N, McHale JM, Dabbous OH. Pediatric Gastroesophageal Reflux Disease and Acid-Related Conditions: Trends in Incidence of Diagnosis and Acid Suppression Therapy. *Journal of Medical Economics*. 2009; 12(4):348-55.
133. **Wu EQ**, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. Frequency, Risk, and Cost of Gout-Related Episodes among the Elderly: Does Serum Uric Acid Level Matter? *The Journal of Rheumatology*. 2009; 36(5): 1032-40. Epub 2009 Apr 15.
134. Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, **Wu EQ**, Chao J, Mulani PM. Cost Utility Ofadalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease. *PharmacoEconomics*. 2009; 27(7):609-21.
135. **Wu EQ**, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment Persistence, Healthcare Utilization and Costs in Adult Patients with Major Depressive Disorder: A Comparison between Escitalopram and other SSRI/SNRIs. *Journal of Medical Economics*. 2009; 12(2):124-35.
136. Frois C, **Wu EQ**, Ray S, Colice GL. Inhaled Corticosteroids Or Long-Acting B-Agonists Alone or in Fixed-Dose Combinations in Asthma Treatment: A Systematic Review of Fluticasone/Budesonide and Formoterol/Salmeterol. *Clinical Therapeutics*. 2009 Dec; 31(12) 2779-99.
137. Kothari S, Nelson SP, **Wu EQ**, Beaulieu N, McHale JM, Dabbous OH. Healthcare costs of GERD and Acid-Related Conditions in Pediatric Patients with Comparison Between Histamine-2 Receptor Antagonists and Proton Pump Inhibitors. *Current Medical Research and Opinion*. 2009 Nov; 25(11):2703-9.
138. Loftus EV Jr, Johnson SJ, Yu AP, **Wu EQ**, Chao J, Mulani PM. Cost-effectiveness of Adalimumab for the Maintenance of Remission in Patients with Crohn's Disease. *European Journal of Gastroenterology & Hepatology*. 2009 Nov; 21(11):1302-9.
139. Yu AP, Tang J, Xie J, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Economic Burden of Psoriasis Compared to the General Population and Stratified by Disease Severity. *Current Medical Research and Opinion*. 2009 Oct; 25(10):2429-38.
140. **Wu EQ**, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM. Impact of Sustained Remission and Clinical Response on the Risk Of Hospitalization in Patients with Crohn's Disease. *Managed Care Interface*, 2008.
141. Loftus EV, Feagan BG, Colombel JF, Rubin DT, **Wu EQ**, Yu AP, Pollack PF, Chao J, Mulani P. Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn's Disease: Patient- Reported Outcomes of the CHARM Trial. *American Journal of Gastroenterology*. 2008 Dec; 103(12):3132-41. Epub 2008 Oct 3.
142. **Wu EQ**, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization Pattern of Etanercept and its Cost Implications in Moderate to Severe Psoriasis in a Managed Care Population. *Current Medical Research and Opinion*. 2008 Dec; 24(12):3493-501.
143. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, **Wu EQ**, Chao J, Mulani P. Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results from the CHARM Study. *Gastroenterology*. 2008 Nov; 135(5):1493-9. Epub 2008 Aug 3.

144. **Wu EQ**, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH. Comparison of Treatment Persistence, Hospital Utilization and Costs among Major Depressive Disorder Geriatric Patients Treated with Escitalopram versus other SSIR/SNRI Antidepressants. *Current Medical Research and Opinion*. 2008 Oct; 24(10):2805-13. Epub 2008 Aug 27.
145. **Wu EQ**, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payer Perspective. *Value in Health*. 2008 Sep-Oct; 11(5): 820-9. Epub 2008 May 16.
146. **Wu EQ**, Greenberg PE, Yang E, Yu A, Erder MH. Comparison of Escitalopram versus Citalopram for the Treatment of Major Depressive Disorder in a Geriatric Population. *Current Medical Research and Opinion*. 2008 Sep; 24(9):2587-95. Epub 2008 Jul 31.
147. **Wu EQ**, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective Claims Data Analysis of Dosage Adjustment Patterns of Tnf Antagonists among Patients with Rheumatoid Arthritis. *Current Medical Research and Opinion*. 2008 Aug; 24(8):2229-40. Epub 2008 Jun 23.
148. Xie J, **Wu EQ**, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported Health Status in Coronary Heart Disease in the United States: age, sex, racial, and ethnic differences. *Circulation*. 2008 Jul 29, 118(5):491-7. Epub 2008 Jul 14.
149. **Wu EQ**, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E. Disease-related and Total Health Care Costs of Gout Patients of Elderly Patients with Gout. *Journal of Managed Care Pharmacy*. 2008 March; 14(2):164-175.
150. Yu AP, Cabanilla LA, **Wu EQ**, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. *Current Medical Research and Opinion*. 2008 Feb; 24(2):319-28.
151. Shi L, **Wu EQ**, Hodges M, Yu AP, Birnbaum HG. Retrospective Economic and Outcomes Analyses using Non-US Databases: A Review. *Pharmacoeconomics*. 2007; 25(7):563-76.
152. Sullivan PW, Ghushchyan V, Wyatt HR, **Wu EQ**, Hill JO. The Impact of Cardiometabolic Risk Factor Clusters on Health-Related Quality of Life in the US. *Obesity*. 2007; 15(2):511-21.
153. **Wu EQ**, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ. Impact of Single-Photon Emission Computed Tomography (SPECT) use after Acute Myocardial Infarction (AMI) on cardiac procedure rates and hospital length of stay. *Journal of Nuclear Cardiology*. 2007; 14(4):S115.
154. Sullivan PW, Ghushchyan V, Wyatt HR, **Wu EQ**, Hill JO. Productivity Costs Associated with Cardiometabolic Risk Factor Clusters in the United States. *Value in Health*. 2007 Nov-Dec; 10(6):443-50.
155. **Wu EQ**, Mulani P, Farrell, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D Health Utility in Metastatic Hormone-Refractory Prostate Cancer Patients. *Value in Health*. 2007 Sep-Oct; 10(5):408-14.
156. **Wu EQ**, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder who received Alternative Drug Therapies. *Journal of Managed Care Pharmacy*. 2007 Sep; 13(7):561-9.
157. **Wu EQ**, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S. Estimated Prevalence of Peripheral Neuropathy and Associated Pain in Adults with Diabetes in France. *Current Medical Research and Opinion*. 2007 Sep; 23(9):2035-42.

158. Yu AP, **Wu EQ**, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A. Short Term Economic Impact of Body Weight Change among Patients with Type 2 Diabetes Treated with Antidiabetic Agents. *Current Medical Research and Opinion*. 2007 Sep; 23(9):2157-69.
159. **Wu EQ**, Chen L, Birnbaum HG, Yang E, and Cifaldi M. Costs of Care for Patients with Rheumatoid Arthritis Receiving TNF-antagonist therapy. *Current Medical Research and Opinion*. 2007 Aug; 23(8):1749-59.
160. Colice G, **Wu EQ**, Birnbaum HG, Daher M, Marynchenko MB. Use of Inhaled Corticosteroids and Healthcare Costs in Mild Persistent Asthma. *Journal of Asthma*. 2007 Jul-Aug; 44(6):479-83.
161. **Wu EQ**, Birnbaum HG, Mareva M, Parece A, Huang Z, Mallett D, Taitel H. Interstitial Cystitis (Ic) Cost, Treatment and Comorbidities in an Employed Population. *Pharmacoeconomics*. 2006; 24(1):55-65.
162. **Wu EQ**, Ben-Hamadi R, Birnbaum HG, Farrell MH, Spalding J, Stang P, Hartmann KE. Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer's Perspective. *Drug Benefit Trends*. 2006; 18(7):405-10.
163. **Wu EQ**, Shi L, Birnbaum HG, Hudson T, Kessler RC. Annual Prevalence of Diagnosed Schizophrenia in the United States: A Claims Data Analysis Approach. *Psychological Medicine*. 2006 Nov; 36(11):1535-40. Epub 2006 Aug 15.
164. Hartmann KE, Birnbaum HG, Ben-Hamadi R, **Wu EQ**, Farrell MH, Spalding J, Stang P. Annual Costs Associated with Diagnosis of Uterine Leiomyomata. *Obstetrics & Gynecology*. 2006 Oct; 108(4):930-7.
165. Xie J, **Wu EQ**, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR. Impact of Stroke on Health-Related Quality of Life in the United States. *Stroke*. 2006 Oct; 37(10):2567-72. Epub 2006 Aug 31.
166. **Wu EQ**, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G. Development of a COPD Severity Score. *Current Medical Research and Opinion*. 2006 Sep; 22(9):1679-87.
167. Colice G, **Wu EQ**, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese S. Healthcare and Workloss Costs Associated with Persistent Asthma Patients in a Privately Insured Population. *Journal of Occupational and Environmental Medicine*. 2006 Aug; 48(8):794-802.
168. **Wu EQ**, Birnbaum HG, Mareva MN, Kim Le T, Robinson RL, Rosen A, Gelwicks S. Cost-effectiveness of Duloxetine versus Routine Treatment for U.S.. Patients with Diabetic Peripheral Neuropathic Pain. *The Journal of Pain*. 2006 Jun; 7(6):399-407.
169. **Wu EQ**, Birnbaum HG, Kang Y, Parece A, Mallett D, Taitel H, Evans RJ. A Retrospective Claims Database Analysis to Assess Patterns of Interstitial Cystitis (IC) Diagnosis. *Current Medical Research and Opinion*. 2006 Mar; 22(3):495-500.
170. Kessler RC, Birnbaum HG, Demler O, Falloon IR, Gagnon E, Guyer M, Howes M, Kendler KS, Shi L, Walters EE, **Wu EQ**. The Prevalence and Correlates of Non-Affective Psychosis in the National Comorbidity Survey Replication (NCS-R). *Biological Psychiatry*. 2005 Oct 15; 58(8):668-76. Epub 2005 Jul 14.
171. **Wu EQ**, Birnbaum HG, Mareva M, Edward Tuttle, Jackman W, Ruskin J. Economic Burden and Comorbidities of Atrial Fibrillation in an Employed Population. *Current Medical Research and Opinion*. 2005 Oct; 21(10):1693-9.
172. **Wu EQ**, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The Economic Burden of Schizophrenia in the United States in 2002. *Journal of Clinical Psychiatry*. 2005 Sep; 66(9):1122-9.

173. **Wu EQ**, Birnbaum HG, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with Overactive Bladder: Work Loss Burden. *Journal of Occupational and Environmental Medicine*. 2005 May; 47(5):439-46.

### **Book Chapter**

- Liu G, Cai R, Chao S, Xiong X, Zhao Z, **Wu EQ**, China's Urban Health Insurance Reform Experiment In Zhenjiang: Cost And Utilization Analyses, *The Economics of Health Care in Asia-Pacific Countries*, Edward Elgar Publishing Limited, 2002.

### **Selected Conference Presentations**

1. Gauthier G, Guerin G, Zhdanava M, **Wu EQ**, Masaquel A, Barnett B. A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond. Poster accepted for presentation at the 2015 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. December 8-12, 2015.
2. Cloutier M, Guerin A, Heroux J, Emond B, Q. **Wu EQ**, Masaquel A, Barnett B. What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine? Poster accepted for presentation at the 2015 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. December 8-12, 2015.
3. Li N, Hao Y, Lin PL, Koo V, Ohashi E, **Wu EQ**, Xie J. Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2- metastatic breast cancer patients with leiver metastasis or multiple metastatic sites. Poster accepted for presentation at the 2015 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. December 8-12, 2015.
4. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, **Wu EQ**. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites. Poster accepted for presentation at the 2015 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA. December 8-12, 2015.
5. Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, **Wu EQ**, Thomas S, Chen L. Five-Year Direct Cost of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL) Undergoing Allogeneic Stem Cell Transplantation (HSCT): An Analysis from US Payers' Perspective Accepted for oral presentation at the 57th ASH Annual Meeting and Exposition, Orlando FL. December 5-8, 2015.
6. Guerin A, Ray S, Gauthier G, Hsu L, Zhdanava M, **Wu EQ**. The Healthcare Resource Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients. Accepted for poster presentation at the 57th ASH Annual Meeting and Exposition, Orlando FL. December 5-8, 2015.
7. Ko J, Nazareth T, Frois C, Carpenter S, Demean S, **Wu EQ**, Sasane R, Navarro R. Outcomes-Based Pricing and Reimbursement Arrangements for Pharmaceutical Products in the U.S. and EU-5: Payer and Manufacturer Experience and Outlook. Poster has been accepted (in the professional non-reviewed/encore category) for AMCP Nexus 2015, Gaylord Palms Hotel & Convention Center, Orlando FL. October 26-29, 2015
8. Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, **Wu EQ**, Macalalad A. Symptoms of Bone and Liver Metastases in Patients with ALK+ Non-Small Cell Lung Cancer (NSCLC). Abstract has been accepted for poster presentation at the 16th World Conference on Lung Cancer, Denver, CO. September 6-9, 2015

9. Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, **Wu EQ**. Comparative Effectiveness Of Everolimus Versus Endocrine Monotherapies Among Post-Menopausal Women With HR+/HER2- Metastatic Breast Cancer: A Retrospective Chart Review of Community Oncology Practices in the US. ASCO 2015 Annual Meeting, Chicago, IL, May 29 – June 6, 2015.
10. Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, **Wu EQ**. Comparative Effectiveness Of Everolimus Versus Chemotherapies Among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer: A Retrospective Chart Review of Community Oncology Practices in the US. ASCO 2015 Annual Meeting, Chicago, IL, May 29 – June 6, 2015
11. Vazquez B, Sidovar M, Squillacote D, **Wu E**, Macaulay D, Sorg R, Guo A. Healthcare Resource Utilization Associated with Rescue Medication use in Adult Patients with Seizure Clusters: A Retrospective Chart Review. Poster presented at the ISPOR 20th Annual International Meeting at the Philadelphia Marriott Downtown in Philadelphia, PA from May 16-20, 2015.
12. Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR, Ohashi E, Zhou Z, **Wu EQ**. Treatment Patterns of Endocrine Therapy and Chemotherapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer. Poster presented at the ISPOR 20th Annual International Meeting at the Philadelphia Marriott Downtown in Philadelphia, PA from May 16-20, 2015.
13. Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, **Wu EQ**. Comparative Effectiveness of Everolimus vs. Fulvestrant Monotherapy among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer. Poster presented at the ISPOR 20th Annual International Meeting at the Philadelphia Marriott Downtown in Philadelphia, PA from May 16-20, 2015.
14. Soliman AM, Fuldeore M, Yang H, Du EX, **Wu EQ**, Winkel C. Treatment Patterns of Women Diagnosed with Uterine Fibroids 5 Years Pre and Post Diagnosis: A Longitudinal Retrospective Claims Analysis of a Commercially Insured Population in the US. Poster presented at the ISPOR 20th Annual International Meeting at the Philadelphia Marriott Downtown in Philadelphia, PA from May 16-20, 2015.
15. Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, **Wu EQ**, Sasane R, Navarro R. Outcomes-based Pricing and Reimbursement Arrangements for Pharmaceutical Products in the US and EU-5: Payer and Manufacturer Experience and Outlook. Poster presented at the ISPOR 20th Annual International Meeting at the Philadelphia Marriott Downtown in Philadelphia, PA from May 16-20, 2015.
16. Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, **Wu EQ**. Overall Survival with First Line Endocrine Therapy or Chemotherapy among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer: A Retrospective Chart Review Study in the US. Poster presented at the AMCP 27th annual conference in San Diego, California from April 7-10, 2015.
17. Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, **Wu EQ**. Overall Survival Following Initiation of first-Line Treatment with a Non-Steroidal Aromatase Inhibitor or Fulvestrant among Post-Menopausal Women with Recurrent HR+/HER2- Metastatic Breast Cancer. Poster presented at the AMCP 27th annual conference in San Diego, California from April 7-10, 2015.
18. Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, **Wu EQ**. Treatment Patterns and Predictors of Everolimus Use among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer in the US: A Retrospective Chart Review Study. Poster presented at the AMCP 27th annual conference in San Diego, California from April 7-10, 2015. (Bronze medal winning abstract)

19. Guérin A, Sasane M, Nitulescu R, Zhang J, Culver K, **Wu EQ**. Economic Burden of Bone and Liver Metastases in Patients with ALK+ Non-Small Cell Lung Cancer. Poster presented at the AMCP 27th annual conference in San Diego, California from April 7-10, 2015.
20. Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin P, Ohashi E, Zhou Z, **Wu EQ**. Duration of Treatment by Line of Therapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer. Poster presented at the AMCP 27th Annual Meeting & Expo in San Diego, California from April 7-10, 2015.
21. Nazareth T, Ko J, Frois C, Carpenter S, Demean S, **Wu E**, Sasane R, Navarro R. Outcomes-Based Contracting for Pharmaceutical Products in the United States: Payer And Manufacturer Experience And Outlook. Poster Presented at AMCP's 27th Annual Meeting & Expo in San Diego, CA April 7-10, 2015.
22. Song Y, Hao Y, Macalalad AR, Lin P, Signorovitch JE, **Wu EQ**. Overall Survival Following Initiation of First-Line Treatment with a Non-Steroidal Aromatase Inhibitor of Fulvestrant among Post-Menopausal Women with Recurrent HR+/HER2 Metastatic Breast Cancer. Poster presented at the 2015 BMT Tandem Meeting, San Diego, CA, February 11-15, 2015.
23. Macalalad AR, Yang H, Zhou Z, **Wu EQ**, Chaudhari P, Snyderman DR. Economic Consequences of Cytomegalovirus Disease Among Stem Cell Transplant Recipients. Poster presented at the 2015 BMT Tandem Meeting, San Diego, CA, February 11-15, 2015.
24. Gallagher CM, More KF, Sicignano N, Masaquel A, Barnett B, Kamath T, Guérin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, **Wu EQ**. Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer. Presented at 2014 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, December 9-13, 2014
25. Smith BD, Liu J, Latremouille-Viau D, Zhou Z, Guérin A, Fernandez D, Yi D, Wang X, **Wu EQ**, Mhatre SK, Keir C, Chen L. Comparison of Survival Rates, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as Second-Line Therapy. Poster presented at the 56th ASH Annual Meeting and Exposition, Moscone Center, San Francisco, CA, December 6-9, 2014.
26. Smith BD, Liu J, Latremouille-Viau D, Zhou Z, Guérin A, Fernandez D, Yi D, Wang X, **Wu EQ**, Mhatre SK, Keir C, Chen L. A Retrospective Analysis of Treatment Patterns in Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as Second-Line Therapy after Imatinib. Poster Presented at the 56th ASH Annual Meeting and Exposition, Moscone Center, San Francisco, CA, December 6-9, 2014.
27. Guo A, Rabinowicz A, Squillacote D, Roberts H, Sidovar M, **Wu EQ**, Macaulay D. Clinical Characteristics and Treatment Pattern in Cluster Seizures: A Preliminary Chart Review Analysis. Presented at 2014 Annual Meeting of the American Epilepsy Society, Seattle, WA, USA, December 5-9, 2014.
28. Gallagher CM, More K, Masaquel AS, Kamath T, Guérin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Barnett B, **Wu EQ**. Overall Survival in Patients with HER2 + Early Stage Breast Cancer Patients Treated with Trastuzumab in the US Department of Defense Practice Setting. Poster presented at ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, November 8-12, 2014.
29. Signorovitch J, Betts KA, Meng X, Zhuo Y, **Wu EQ**, Shi L. Which Newly-Diagnosed Diabetics Should Receive Dietary Counseling Services? Estimating Individualized Treatment Allocations That Optimize Cost-Effectiveness in Real-World Data. Presented at ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, November 8-12, 2014.

30. Guérin A, Sasane M, Zhang J, Culver K, Macalalad A, Nitulescu R, **Wu E**, Dea K. Economic Burden and Treatments of Progression to Metastatic Disease in ALK + NSCLC Patients. Poster presented at 2014 Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, USA, October 30-November 1, 2014.
31. Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, **Wu EQ**, Guérin A. Description of ALK+ NSCLC Patient Characteristics and ALK Testing Patterns. Poster presented at 2014 Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, USA, October 30-November 1, 2014.
32. Langer C, Ravelo A, Hazard SJ, Guérin A, Ionescu-Ittu R, Latremouille-Viau D, **Wu EQ**, Ramalingam S. Overall Survival and Hospitalization Rates in Medicare Patients Diagnosed with Advanced NSCLC Treated With Bevacizumab-Carboplatin- Paclitaxel vs Carboplatin-Paclitaxel: A Retrospective Cohort Study. 15th World Conference on Lung Cancer, Sydney, Australia, October 27-30, 2013
33. Lacy B, Patel H, Guérin A, Dea K, Alaghband R, **Wu EQ**, Scopel JL, Mody R. Regional Variation of Care for Irritable Bowel Syndrome in the United States. Poster presented at ACG 2014, Philadelphia, PA, USA, October 17-22, 2014.
34. Lacy B, Patel H, Guérin A, Dea K, Alaghband R, **Wu EQ**, Scopel JL, Mody R. Age-Related Health Care Disparities in Patients with Irritable Bowel Syndrome: Findings from a Sample of Commercially Insured Patients. Poster presented at ACG 2014, Philadelphia, PA, USA, October 17-22, 2014.
35. Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, **Wu EQ**. Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers. Presented at ACMP 2014 Nexus Meeting, Boston, MA, October 7-10, 2014.
36. Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, **Wu EQ**, Guérin A. Economic Burden of Brain Metastases among Lung Cancer Patients. Poster presented at AMCP 2014 Nexus Meeting, Boston, MA, October 7-10, 2014.
37. Gibney GT, Gauthier G, Ayas C, Galebach P, **Wu EQ**, Yim YM, Abhyankar CR, Guérin A. Predictors of Treatment (tx) Response and Progression in BRAF V600E Metastatic Melanoma (mM) Patients (pts) with Brain Metastases (BM) Receiving Vemurafenib (vem) in a Real-World Setting. Poster presented at ESMO 2014 Congress, Madrid, Spain, September 26-30, 2014.
38. Guérin A, Sasane M, Keir C, Gauthier G, Macalalad A, **Wu EQ**, Conley AP. Association between Risk of Recurrence Assessment and Adjuvant Treatment (Tx) Duration in Patients (Pts) with Resected Gastrointestinal Stromal Tumors. Poster presented at ESMO 2014 Congress, Madrid, Spain, September 26-30, 2014.
39. Guérin A, Wakelee H, Sasane M, Zhang J, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, **Wu EQ**, Macalalad AR. Treatment and Survival Patterns among ALK+ NSCLC Patients Following Crizotinib Discontinuation. Poster presented at ISPOR 19th Annual International Meeting, Montreal, QC, Canada; May 31-June 4, 2014.
40. Chen L, Signorovitch JE, **Wu EQ**, Betts KA, Reichmann WM, Thomason D, Galebach PJ. One-Year and Longer-Term Molecular Responses to Nilotinib and Dasatinib for Newly Diagnosed Chronic Myeloid Leukemia: A Matching-Adjusted Indirect Comparison. Poster presented at the ASCO Annual Meeting, Chicago, IL, USA, June 30-July 3, 2014 (suppl abstract 7072).
41. Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, **Wu EQ**. Economic Impact of Switching from Metoprolol to Nebivolol for the Treatment of Hypertension. Poster presented at the American Association of Nurse Practitioners 2014 National Conference, Nashville, Tennessee, USA, June 17-22, 2014.

42. Soliman AM, Fuldeore MJ, Yang H, Du EX, **Wu EQ**, Winkel CA. C Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago.
43. Guérin A, Conley AP, Huang Q, Sasane M, **Wu EQ**, Macalalad AR, Keir CH, Schwiep F. Impact of Underestimation of Risk on Treatment Duration and Recurrence in GIST Patients. Poster presented at 2014 ASCO Annual Meeting, Chicago, IL, USA, May 30-June 3, 2014.
44. Guérin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, **Wu EQ**, Macalalad AR. Symptomatic and Economic Burden of Brain Metastases in Patients with ALK+ NSCLC. Poster presented at 2014 ASCO Annual Meeting, Chicago, IL, USA, May 30-June 3, 2014.
45. Marynchenko M, Galebach P, Ayas C, Liu N, **Wu EQ**, Guérin A. Treatment Patterns and Outcomes in BRAF V600E Mutant Melanoma Patients with Brain Metastases Receiving Vemurafenib in the Real-World Setting. Poster presented at ASCO 50th Annual Meeting, Chicago, IL, US, May 30-June 3, 2014.
46. Sasane M, Wakelee H, Guérin A, Zhang J, Macalalad A, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, **Wu EQ**. Description of ALK+ NSCLC Patient Characteristics and ALK Testing Patterns. Poster presented at 2014 ASCO Annual Meeting, Chicago, IL, USA, May 30- June 3, 2014.
47. Conley AP, Sasane M, Guérin A, Macalalad AR, Huang Q, Schwiep F, **Wu E**. Underestimation of the Risk of Recurrence in Patients with Primary Resected Gastrointestinal Stromal Tumors. Poster presented at NCCN 19th Annual Conference, Hollywood, FL, US, March 13-15, 2014.
48. Bollu V, Velez F, Cloutier M, Guérin A, Carter V, Héroux J, Dea K, **Wu EQ**. Impact of Treatment- Associated Adverse Events on Healthcare Resource Utilization and Costs among Patients with Partial Onset Seizures: A Longitudinal Analysis. Poster presented at American Epilepsy Society (AES) Meeting, Washington, DC, USA, December 6-10, 2013.
49. Velez F, Bollu V, Cloutier M, Guérin A, Carter V, Héroux J, Nitulescu R, **Wu EQ**. The Economic Burden of Central Nervous System Events among Patients with Partial Onset Seizures Treated with Antiepileptic Drugs. Poster presented at American Epilepsy Society (AES) Meeting, Washington, DC, USA, December 6-10, 2013.
50. Guérin A, Chen L, **Wu EQ**, Dea K, Goldberg S. Impact of Regular Molecular Monitoring on Tyrosine Kinase Inhibitor Therapy Adherence In Chronic Myelogenous Leukemia in the Chronic Phase. Poster presented at 2013 ACCP Annual Meeting, Albuquerque, NM, USA, October 13-16, 2013.
51. Guérin A, Mody R, Carter V, **Wu EQ**. Impact of the FDA Safety Communication on Prescription Trends of Clopidogrel in Combination with Proton Pump Inhibitors. Poster presented at American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting and Postgraduate Course, San Diego, CA, USA, October 11-16 , 2013.
52. Bron M, Guérin A, Latremouille-Viau D, Ionescu-Ittu R, Lopez C, Viswanathan P, **Wu EQ**. Distribution of Costs in Patients with Type 2 Diabetes Mellitus: A Retrospective Claims Database Analysis. Poster presented at 49th Annual Meeting, Barcelona, Spain, September 23-27, 2013.
53. Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guérin A, Samp J, **Wu EQ**. Cost Predictors in Type 2 Diabetes Mellitus: A Retrospective Claims Database Analysis. Poster presented at 49th Annual Meeting, Barcelona, Spain, September 23-27, 2013.

54. Yan S, Warusavitarne J, Yang M, van den Broek N, **Wu EQ**, Thomason D, Hoch J. Vitala™ Continence Control Device vs. Traditional Pouch System: A Comparison of Health-Related Quality-of-Life. Poster presented at 12th European Council of Enterostomal Therapy Congress, Paris, France, June 23-26, 2013.
55. Chaudhari P, Yang H, Zhou ZY, Patel C, **Wu EQ**. Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex for Treating Invasive Fungal Infections in Hospitalized Patients. Poster presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May 18-22, 2013.
56. De G, Yang H, Runken MC, Yan Y, Kelkar S, Bui CN, Xie J, **Wu EQ**. Impact of Mirabegron Treatment And Symptom Severity on Work Productivity and Activity Impairment in Patients with Overactive Bladder. Poster presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May 18-22, 2013.
57. Kan H, Guérin A, **Wu EQ**, Kaminsky M, Yu AP, Denio AE, Jhingran PM, Molta CT, Narayanan S. Health Care Resource Utilization (HRU) and Costs Associated with Disease Activity in SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A Retrospective Observational Cohort Analysis. Poster presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May18-22, 2013.
58. Shi L, Ye X, Lu M, **Wu EQ**, Sharma H, Thomason D, Fonseca V. Economic Outcomes Associated with HBA1C and LDL-C Goal Achievement in Patients with Type 2 Diabetes Mellitus. Poster presented at ISPOR18th Annual International Meeting, New Orleans, LA, USA, May 18-22, 2013.
59. Signorovitch J, Chopra P, Cheng D, Ayyagari R, **Wu EQ**. Beyond Average Adherence: Temporal Patterns of Medication Adherence Predict Hospitalization Risk more Accurately than the Medication Possession Ratio. Podium presentation at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May18-22, 2013.
60. Signorovitch J, Ayyagari R, Cheng D, **Wu EQ**. Matching-Adjusted Indirect Comparisons: A Simulation Study of Statistical Performance. Poster presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May18-22, 2013.
61. **Wu EQ**, Xie J, Du EX, Ming L, Liu G. Trend in Economic Burden of Diabetes in Urban China from 2009 to2011. Poster presented at ISPOR 18th Annual International Meeting, New Orleans, LA, USA, May 18-22, 2013.
62. Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, **Wu EQ**, Santos E. Comparison of Healthcare Resource Utilization and Costs Between Patients who Received Trastuzumab in an Outpatient Hospital vs. Office Clinic Setting for the Treatment of Breast Cancer. Poster presented at AMCP 25th Annual Meeting & Expo, San Diego, CA, USA, April 3-5, 2013.
63. Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, **Wu EQ**. Medical Costs Associated with Treatment Failure with Over-the-Counter or Prescription Constipation Treatments in Patients with IBS-C in a Medicaid Population. Poster presented at AMCP 25th Annual Meeting & Expo, San Diego, CA, USA, April 3-5, 2013.
64. DeAngelo DJ, Chen L, Guérin A, Styles A, Giguere-Duval P, Aberki C, **Wu EQ**. Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. Poster presented at 54th ASH Annual Meeting and Exposition, Atlanta, GA USA, December 8-11, 2012.
65. Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guérin A, Liu N, Kaminsky M, **Wu EQ**. Frequency of Molecular Monitoring Correlates with Long Term Outcomes in Chronic Phase Chronic Myelogenous Leukemia Treated with First-Line Imatinib: Results of a Community Survey. Poster presented at 54th ASH Annual Meeting and Exposition, Atlanta, GA USA, December 8-11, 2012.

66. Griffin JD, Chen L, Guérin A, Macalalad AR, Luo J, **Wu EQ**. Comparison of Disease Outcomes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib as Second-Line Therapy. Poster presented at 54th ASH Annual Meeting and Exposition, Atlanta, GA USA, December 8-11, 2012.
67. Griffin JD, Chen L, Guérin A, Macalalad AR, Luo J, **Wu EQ**. Characteristics of Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched to Nilotinib or Dasatinib As Second-Line Therapy. Poster presented at 54th ASH Annual Meeting and Exposition, Atlanta, GA USA, December 8-11, 2012.
68. Griffin JD, Chen L, Guérin A, Macalalad AR, Luo J, **Wu EQ**. Comparison of Treatment Changes for Patients with Chronic Myelogenous Leukemia in Chronic Phase Switched From Imatinib to Nilotinib or Dasatinib. Poster presented at 54th ASH Annual Meeting and Exposition, Atlanta, GA USA, December 8-11, 2012
69. Gauthier G, Guérin A, Styles A, **Wu EQ**, Masaquel A, Brammer MG, Lalla D. Comparison of Treatment Patterns and Outcomes in Metastatic Breast Cancer Patients Initiated on Trastuzumab vs. Lapatinib; A Retrospective Analysis. Poster presented as San Antonio Breast Cancer Symposium, San Antonio, TX, USA December 4-8, 2012.
70. Conley A, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir C, **Wu EQ**. Investigation of Gastrointestinal Stromal Tumor (gist) Care Management in Gist Patients (pts) Receiving Short-Term vs. Long-Term Imatinib (im) Adjuvant Therapy – A Chart Review Analysis. Poster presented at 2012 ASCO Quality of Care Symposium, San Diego, CA, USA, October 30-November 1, 2012.
71. Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, **Wu EQ**, Samuelson TM, Faust E, Emery P. Risk Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab plus Methotrexate vs. Methotrexate alone. Poster presented at 2012 ACR/ARHP Annual Meeting Annual Meeting, Washington, D.C., USA, November 9-14, 2012.
72. Xie J, Ganguli A, Yang HY; Parikh K, **Wu EQ**, Cifaldi M. Comparison of Rheumatoid Arthritis-Related Health Care Resource use and Comorbidities among Patients with Rheumatoid Arthritis Treated with Adalimumab vs. Etanercept. Poster presented at 2012 ACR/ARHP Annual Meeting Annual Meeting, Washington, D.C. USA, November 9-14, 2012.
73. Bron M, Chen KS, Ayyagari R, Sharma H, **Wu EQ**. HbA1c Reduction Associated with Initial vs. Sequential Combination Therapy with Pioglitazone (PIO) and Dipeptidyl Peptidase-4 Inhibitors (DPP4i) in Patients with Type 2 Diabetes Mellitus (T2DM). Poster presented at ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012.
74. Hurvitz SA, Guérin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, **Wu EQ**, Lalla D. Comprehensive Investigation of Adverse Event (age)-Related Costs in Patients with Metastatic Breast Cancer (MBC) Treated with First- and Second-Line Chemotherapies. Poster presented at ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012.
75. Xie J, Zhou ZY, Bui CN, Yan SY, De G, Runken CM, **Wu EQ**. Cost-Effectiveness Analysis of Mirabegron vs. Tolterodine Extended-Release in the Treatment of Patients with Overactive Bladder in the United States. Poster presented at ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012.
76. Ayyagari R, Cheng D, Xie J, Huang XY, **Wu EQ**, Chen S. Tolerability and Effectiveness of Nebivolol Compared to other Add-on Therapies for Hypertension: A Retrospective Chart Review. Poster presented at Canadian Hypertension Congress, Toronto, Canada, October 25-28, 2012.

77. Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, **Wu EQ**. Period Prevalence of Stimulant Augmentation among Pediatric Attention Deficit/Hyperactivity Disorder (ADHD) Patients during 2009: A Retrospective Analysis of a Managed Care Population. Poster presented at 59th AACAP Annual Meeting, San Francisco, CA, USA, October 23-28, 2012
78. Ali T, Yang M, Skup M, Yang M, **Wu EQ**, Chao J, Mulani PM. Cost-Effectiveness Model of Adalimumab for the Treatment of Moderate to Severe Ulcerative Colitis in the United Kingdom. Poster presented at 20th United European Gastroenterology Week, Amsterdam, The Netherlands, October 20-24, 2012.
79. Guérin A, Mody R, Fok B, Zhou ZY, **Wu EQ**, Zhou W, Lasch KL, Talley NJ. Prevalence and Risk of Developing Gastrointestinal Conditions in Patients with Chronic Constipation. Poster presented at ACG Annual Scientific Meeting, Las Vegas, Nevada, USA, October 19-24, 2012.
80. Guérin A, Mody R, Fok B, Zhou ZY, **Wu EQ**, Zhou W, Lasch KL, Talley NJ. Prevalence and Risk of Developing Non-Gastrointestinal Physical and Mental Comorbidities in Patients with Chronic Constipation. Poster presented at ACG Annual Scientific Meeting, Las Vegas, Nevada, USA, October 19-24, 2012.
81. Guérin A, Mody R, Fok B, Zhou ZY, **Wu EQ**, Zhou W, Lasch KL, Talley NJ. Risk Of Developing Colorectal Cancer and Benign Neoplasm in Patients with Chronic Constipation. Poster presented at ACG Annual Scientific Meeting, Las Vegas, Nevada, USA, October 19-24, 2012.
82. Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, **Wu EQ**, Erder MH. A Comparison of Rates and Reasons for Urgent Care Utilization among Children with ADHD Treated with atypical antipsychotics vs. Non-antipsychotics. Poster presented at Institute of Psychiatric Services Meeting, New York, NY, USA, October 4-7, 2012.
83. Leahy MJ, Sun SX, Yu AP, Chen KS, **Wu EQ**, Mattson M, Tang J. Comparisons of Costs And Clinical Outcomes in Hypertensive Patients Treated with Angiotensin Receptor Blockers plus Chlorthalidone or Hydrochlorothiazide. Poster presented at AMCP Educational Conference, Cincinnati, Ohio, USA, October 3-5, 2012.
84. Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, **Wu EQ**. Comparisons of Costs and Clinical Outcomes in Hypertensive Patients Treated with Chlorthalidone or Hydrochlorothiazide. Poster presented at AMCP Educational Conference, Cincinnati, Ohio, USA, October 3-5, 2012.
85. Chen KS, **Wu EQ**, Cheng D, Bensimon AG, Bron M. Comparison of Clinical and Economic Outcomes Associated with DPP4i versus SU in Combination with MET or PIO for the Treatment of Type 2 Diabetes Mellitus. Poster presented at 48th EASD Annual Meeting, Berlin, Germany, October 1-5, 2012.
86. Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, **Wu EQ**, Mulani PM. Outcomes of Switching to Adalimumab vs. Continuing Methotrexate in Patients with Moderate to Severe Psoriasis Stratified by Initial Response to Methotrexate. Poster presented at 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, September 27-30, 2012.
87. Vander Velde NS, Chen L, Sharma H, Marynchenko M, **Wu EQ**, Liu J, Yang HY, Guo A, Shi L. Real- world Study of Imatinib Treatment Patterns and Outcomes among Veteran Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Poster presented at ESH-iCML International Conference, Baltimore, MD, USA, September 20-23, 2012.

88. Bensimon AG, Bron M, **Wu EQ**, Chen KS, Cheng D. Comparison of Clinical and Economic Outcomes Associated with DPP-4 Inhibitors (DPP-4i) versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM). Poster presented at 5th ISPOR Asia-Pacific Conference, Taipei, Taiwan, September 2-4, 2012.
89. Bron M, Cheng D, Chen KS, Sharma H, **Wu EQ**. Predictors of Reaching HbA1c Goal in T2DM Patients using Dipeptidyl Peptidase-4 Uinhibitors (DPP-4is) Combination Therapy: A Subgroup Analysis. Poster presented at 5th ISPOR Asia-Pacific Conference, Taipei, Taiwan, September 2-4, 2012.
90. Xie K, Wu J, Xie J, Zheng Y, Yang HY, **Wu EQ**. Glycemic Control and Quality of Life for Patients with Type 2 Diabetes Mellitus in China. Poster presented 5th ISPOR Asia-Pacific Conference, Taipei, Taiwan, September 2-4, 2012.
91. Setyawan J, Hodgkins P, **Wu EQ**, Guérin A, Gauthier G, Cloutier M, Erder H. Comparison of Discontinuation Risk in Patients Initiated on Lisdexamfetamine Dimesylate (LDX) vs. Other Medications for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD): A Retrospective Claims Analysis. Poster presented at 20th World Congress of the IACAPAP, Paris, France, July 21-25, 2012.
92. Hurvitz SA, Guérin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, **Wu EQ**, Lalla D. Comprehensive Investigation of Adverse Event (age)-Related Costs in Patients with Metastatic Breast Cancer (MBC) Treated with First- and Second-line Chemotherapies. Poster presented at MASCC/ISOO 2012 International Symposium, New York, NY, USA, June 28-30, 2012.
93. Carson RT, Guérin A, Lewis B, Yin D, Ramakrishnan K, Kaminsky MS, **Wu EQ**. The Economic Burden of Unmet Treatment Needs in Medicaid Patients with Chronic Constipation. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012.
94. Setyawan J, Hodgkins PS, Guérin A, Gauthier G, Cloutier M, **Wu EQ**, Erder MH. Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficity/Hyperactivity Disorder. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012
95. Xie J, Diener M, De G, **Wu EQ**, Namjoshi M. Budget Impact Analysis of Everolimus for ER+, HER2-Metastatic Breast Cancer Patients in the US. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012
96. **Wu EQ**, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J. Economic Burden of Hepatocellular Carcinoma in China. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012
97. Wu J, Xie J, Han R, Wang L, Yang HY, **Wu EQ**. Health Utility for Patients with Type 2 Diabetes Mellitus in China. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012
98. Yang HY, Wu J, Zheng Y, Xie K, Jin L, Xie J, **Wu EQ**. Economic Burden Associated with Acute Exacerbations of Chronic Obstructive Pulmonary Disease in China. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012
99. Zheng Y, **Wu EQ**, Xie K, Zheng B, Yang HY, Xie J, Wu J. Economic Burden of Type 2 Diabetes Mellitus in China. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012
100. Zheng Y, Wu J, Xie J, Xie K, Yang HY, Liu J, **Wu EQ**. Healthcare Utilization and Costs among Lung Cancer Patients in China. Poster presented at ISPOR 17th Annual International Meeting, Washington, DC, USA, June 2-6, 2012

101. Bonthapally V, **Wu EQ**, Guérin A, Gauthier G, Cloutier M, Holen KD, Ray S. Health Care Utilization and Economic Burden of Dermatologic Adverse Drug Reactions (ADRs) in Patients with NSCLC Treated with an Epidermal Growth Factor Receptor Inhibitor (EGFRI). Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
102. Chen L, Guérin A, Guo A, Aberki C, **Wu EQ**, Ericson SG. Monitoring and Switching Patterns In Chronic Myelogenous Leukemia Patients Treated with Imatinib: A Chart Review Analysis. Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
103. Conley A, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir C, **Wu EQ**. Risk of Disease Recurrence and Mortality in Gastrointestinal Stromal Tumor (Gist) Patients Receiving Short-Term versus Long-Term Imatinib Adjuvant Therapy: A Chart Review Analysis. Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
104. Gauthier G, Guérin A, Styles A, **Wu EQ**, Brammer MG, Lalla D. Comparison of Treatment Patterns and Outcomes in Metastatic Breast Cancer (MBC) Patients Initiated on Trastuzumab vs. Lapatinib: A Retrospective Analysis. Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
105. Guérin A, Conley A, Sasane M, Gauthier G, Schwiep F, Keir C, **Wu EQ**. Characteristics of Gastrointestinal Stromal Tumor (GIST) Patients Receiving Short-Term vs. Long-Term Imatinib (IM) Adjuvant Therapy: A Chart Review Analysis. Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
106. Hurvitz SA, Guérin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, **Wu EQ**, Lalla D. Comprehensive Investigation of Adverse Event (AE)-Related Costs in Patients with Metastatic Breast Cancer (MBC) Treated with First- and Second-Line Chemotherapies. Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
107. Shi L, Chen L, Sharma H, Marynchenko M, **Wu EQ**, Liu J, Yang HY, Guo A, Vander Velde NS. Real- World Study of Imatinib Treatment Patterns and Outcomes among Veteran Patients with Chronic Myeloid Leukemia. Poster presented at ASCO Annual Meeting, Chicago, IL, USA, June 1-5, 2012.
108. Xie J, Diener M, **Wu EQ**, Sorg R, Yu AP, Namjoshi M. Number Needed to Treat and Risk Benefit Analysis of Denosumab versus zoledronic Acid in the Treatment of Castrate-Resistant Prostate Cancer Patients with Bone Metastases. Poster presented at American Urological Association Annual Meeting, Atlanta, GA, USA, May 19-23, 2012.
109. Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, **Wu EQ**. Compliance and Persistence With Nebivolol vs. Diuretics as First Add-On Hypertension Treatment. Poster presented at 27th Annual American Society of Hypertension Conference, New York, NY, USA, May 19-22, 2012.
110. Fung G, Kahler K., Xie J, Marynchenko M, **Wu EQ**, Kam I, Yang W. Associations of Hypertension with Risk of Cardiovascular Events among Chinese Stroke Patients in the US. Poster presented at 27th Annual American Society of Hypertension Conference, New York, NY, USA, May 19-22, 2012.
111. Fung G, Kahler K, Xie J, Liu NS, **Wu EQ**, Kam I, Yang W. Risk of Cardiovascular Events Associated with Hypertension among Chinese and Caucasian Stroke Patients in the US. Poster presented at 27th Annual American Society of Hypertension Conference, New York, NY, USA, May 19-22, 2012.
112. Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, **Wu EQ**. Treatment Patterns and Indicators of Unmet Needs in Medicaid Patients with Irritable Bowel Syndrome with Constipation and Chronic Constipation. Poster presented at Digestive Disease Week, San Diego, CA, USA, May 19-22, 2012.

113. Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, **Wu EQ**, Erder MH. A Comparison of Rates and Reasons for Urgent Care Utilization among Children with ADHD Treated with Atypical Antipsychotics vs. Non-Antipsychotics. Poster presented at 165th APA Annual Meeting, Philadelphia, PA, USA, May 5-9, 2012.
114. Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, **Wu EQ**, Erder MH. Urgent Care Utilization for Adolescents Treated with Atypical Antipsychotics or Non-Antipsychotics: A Comparison of Rates and Reasons. Poster presented at 165th APA Annual Meeting, Philadelphia, PA, USA, May 5-9, 2012.
115. Sikirica V, Pliszka SR, Betts KA, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Erder MH, **Wu EQ**. Atypical Antipsychotics vs. non-antipsychotics: Comparative Treatment Patterns, Resource Utilization and Costs in Stimulant-Treated Adolescents with ADHD who require Subsequent Pharmacotherapy. Poster presented at AMCP 24th Annual Meeting & Expo, San Francisco, CA, USA, April 18-20, 2012.
116. Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, **Wu EQ**. The Economic Burden of Treatment Failure in Medicaid Patients with Irritable Bowel Syndrome with Constipation. Poster presented at AMCP 24th Annual Meeting & Expo, San Francisco, CA, USA, April 18-20, 2012.
117. **Wu EQ**, Chaudhari P, Sharma H, Macalalad AR, Horn D. Current Trends in Utilization and Dosage Patterns of Micafungin and Caspofungin in the United States. Poster presented at 11th American Society for Microbiology Conference on Candida and Candidiasis, San Francisco, CA, USA, April 29 -2, 2012.
118. Signorovitch J, Macaulay D, Diener M, Yan S, **Wu EQ**, Gruenberger JB, Frier BM. Hypoglycaemia and Accident Risk in People with Type 2 Diabetes Treated with Antidiabetes Drugs without Insulin. Poster presented at Diabetes UK Professional Conference 2012, Glasgow, UK, March 7-9, 2012.
119. Sandborn WJ, Colombel J-F, Louis E, Panaccione R, Yang M, **Wu EQ**, Yang M, Mulani PM, Chao J. Assessing Preference for Deep Remission in Patients With Crohn's Disease. Poster presented at European Crohn's and Colitis Organisation 7th Congress, Barcelona, Spain, February 16-18, 2012.
120. Xie J, Signorovitch JE, Diener M, Sorg R, **Wu EQ**, Namjoshi M. Number Needed to Treat and Treatment Cost per Fracture Avoided with Denosumab compared to Zoledronic Acid in Breast Cancer Patients with Bone Metastases. Presentation at 11th International Conference Cancer-Induced Bone Disease, Chicago, Illinois, USA, November 30-December 3, 2011.
121. Setyawan J, Hodgkins PS, **Wu EQ**, Guérin A, Gauthier G, Cloutier M, Erder MH. Comparison of Treatment Adherence in Patients Initiated on Lisdexamfetamine Dimesylate vs. other Medications for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Retrospective Study. Poster presented at The American Professional Society of ADHD and Related Disorders, Current Concepts and Future Developments Conference, Philadelphia, PA, USA, November 19, 2011.
122. Shi L, Liu J, Kissinger P, Khan M, **Wu EQ**. Rates and Predictors of Chlamydia Re-Screening among Privately Insured Patients With Chlamydia in 2007- 2009. Poster presented at ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8 , 2011.
123. Sikirica V, Erder MH, Xie J, Macaulay D, Diener M, Hodgkins P, **Wu EQ**. Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared to Stimulant Monotherapy for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents. Poster presented at ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8, 2011.

124. **Wu EQ**, Guérin A, Latremouille-Viau D, Gauthier G, Day R, Khan Z, Zhang F. Economic Burden of Psoriasis and Diabetes in a Population of Patients with Psoriasis in the United States. Poster presented at ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8, 2011.
125. Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu AP, **Wu EQ**, Liu J, Shi L. Uncontrolled Serum Uric Acid is Associated with an Increased Risk of Developing Renal Disease in Veterans with Gout. Poster presented at ACR/ARHP Annual Scientific Meeting, Chicago, IL, USA, November 4-9, 2011.
126. Pandya BJ, Marynchenko M, Sharma H, Yu AP, **Wu EQ**, Shi L, Liu J, Krishnan E. Uncontrolled Serum Uric Acid in Veteran Gout Patients is Associated with a Higher Risk of Diabetes. Poster presented at ACR/ARHP Annual Scientific Meeting, Chicago, IL, USA, November 4-9, 2011.
127. Latremouille-Viau D, Sawicki G, Zhang J, von Wartburg M, Signorovitch JE, **Wu EQ**, Shi L. Effect of Tobramycin Inhalation Solution on Mortality in Subgroups of Patients with Cystic Fibrosis. Poster presented at 25th NACFC Annual Meeting, Anaheim, California, USA, November 3-5, 2011.
128. Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch JE, von Wartburg M, **Wu EQ**, Shi L. Prevalence of Pseudomonas Aeruginosa Infection and Antibiotic Resistance by Age Group in the CFF Patient Registry in 2003 and 2008. Poster presented at 25th NACFC Annual Meeting, Anaheim, California, USA, November 3-5, 2011.
129. **Wu EQ**, Guérin A, Latremouille-Viau D, Gauthier G, Day R, Khan Z, Zhang F. Economic Burden of Psoriasis and Diabetes in a Population of Patients with Psoriasis in the United States. Poster presented at EASD Congress, Lisbon, Portugal, October 20-24, 2011.
130. Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, **Wu EQ**. Treatment Patterns, Resource Utilization, and Costs Associated with Atypical Antipsychotics vs. Non-Antipsychotics added to or switched from Stimulants among Children with Attention-Deficit/Hyperactivity Disorder (ADHD). Poster presented at AMCP Educational Meeting, Atlanta GA, USA, October 19-21, 2011.
131. Yu AP, Sun SX, Marynchenko M, Banerjee R, Mocarski M, Yin D, **Wu EQ**. Cost-Effectiveness Analysis of Roflumilast/ Tiotropium Combination Therapy versus Tiotropium Monotherapy in Patients with Severe to Very Severe COPD. Poster presented at AMCP Educational Meeting, Atlanta GA, USA, October 19-21, 2011.
132. Setyawan J, Hodgkins PS, **Wu EQ**, Guérin A, Gauthier G, Cloutier M, Erder MH. Comparison of Treatment Adherence in Patients Initiated on Lisdexamfetamine Dimesylate (LDX) vs. Other Medications for the Treatment of ADHD: A Retrospective Study. Poster presented at AACAP/CACAP Joint Annual Meeting, Toronto, ON, Canada, October 18-23, 2011.
133. Signorovitch JE, Sikirica V, Lu M, Xie J, **Wu EQ**, Erder MH. Comparative Efficacy of Guanfacine Extended-Release and Atomoxetine for the Treatment of Oppositional Symptoms in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) and Co-Morbid Oppositional Defiant Disorder (ODD). Poster presented at CADDRA 2011 Annual ADHD Conference, Toronto, Ontario, Canada, October 14-16, 2011.
134. Yu AP, Diener M, **Wu EQ**, Namjoshi M. Number Needed to Treat and Risk Benefit Analysis of Denosumab versus Zoledronic Acid in the Treatment of Castrate-Resistant Prostate Cancer Patients with Bone Metastases. Poster presented at the ASBMR Annual Meeting, San Diego, CA, USA, September 16- 20, 2011.
135. Bron M, Marynchenko M, Yang HY, Yang Y, **Wu EQ**, Yu AP. Hypoglycemia in Adult vs. Elderly Type 2 Diabetes Mellitus Patients: Risks, Costs, and Impact on Treatment Persistence in a US Population. Poster presented at EASD 47th Annual Meeting, Lisbon, Portugal, September 12-16, 2011.

136. Yang HY, Marynchenko M, Bron M, **Wu EQ**, Yu AP. Comparison of Hypoglycemia Risk and Cost between Oral Antidiabetic Monotherapies in Elderly Patients with Type 2 Diabetes Mellitus in a US Population. Poster presented at EASD 47th Annual Meeting, Lisbon, Portugal, September 12-16, 2011.
137. Zhou S, **Wu EQ**, Yu AP, Lu M, Sharma H, Graf T. Outcomes Associated with Insulin Therapy Discontinuation after Hospital Discharge in Patients with Type 2 Diabetes Initiated on Insulin During Hospitalization. Presented at the 47th EASD Annual Meeting, Lisbon, Portugal, September 12-16, 2011.
138. **Wu EQ**, Xie J, Signorovitch J, Diener M, Sorg R, and Namjoshi M. Number Needed to Treat and Treatment Cost per Fracture Avoided with Denosumab Compared to Zoledronic Acid in Breast Cancer Patients with Bone Metastases. Poster presented at the 2011 Breast Cancer Symposium, San Francisco, CA, USA, September 8-10, 2011.
139. **Wu EQ**, Zhou S, Yu AP, Lu M, Graf T. Outcomes Associated with Insulin Therapy Discontinuation after Hospital Discharge in Patients with Type 2 Diabetes Initiated on Insulin During Hospitalization. Presented at the ENDO 2011 Annual Meeting, Boston, MA, USA, June 4-7, 2011.
140. Bron M, Marynchenko M, Yang HY, Yang Y, **Wu EQ**, Yu AP. Hypoglycemia in Adult versus Elderly Type 2 Diabetes Mellitus Patients: Risks, Costs, and Impact on Treatment Persistence. Poster presented at ADA 71st Scientific Session, San Diego, CA, USA, June 24-28, 2011.
141. Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, **Wu EQ**. Hypoglycemia Risk Factors among Veterans with Type 2 Diabetes treated with Oral Antidiabetic Drugs. Poster presented at ADA 71st Scientific Session, San Diego, CA, USA, June 24-28, 2011.
142. **Wu EQ**, Zhou S, Yu AP, Lu M, Graf T. Outcomes Associated with Insulin Therapy Disruption After Hospital Discharge in Patients with Type 2 Diabetes. Poster presented at ADA 71st Scientific Session, San Diego, CA, USA, June 24-28, 2011.
143. **Wu EQ**, Zhou S, Yu AP, Lu M, Graf T. Use of Insulin During and After Hospitalization and Factors Associated with Therapy Disruption After Hospital Discharge in Type 2 Diabetes Patients. Poster presented at ADA 71st Scientific Session, San Diego, CA, USA, June 24-28, 2011.
144. Yang HY, Marynchenko M, Bron M, **Wu EQ**, Yu AP. Comparison of Hypoglycemia Risk and Cost between Oral Antidiabetic Monotherapies in Elderly Patients with Type 2 Diabetes Mellitus. Poster presented at ADA 71st Scientific Session, San Diego, CA, USA, June 24-28, 2011.
145. Signorovitch JE, **Wu EQ**, Xie J, Lu M, Sikirica V, Hodgkins P and Erder MH. Comparative Effectiveness Research using Matching-Adjusted Indirect Comparison – A Method for Improving the Reliability and Interpretability of Indirect Comparisons by Incorporating Individual Patient Data. Workshop presented at The 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD, USA, June 6-7, 2011.
146. Wei LJ, Signorovitch JE, **Wu EQ**, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, and Erder MH. Utilizing rich data sources to identify patients' subgroups that can benefit most from a treatment. Workshop presented at The 3rd DEcIDE Symposium On Comparative Effectiveness Research Methods, Baltimore, MD, USA, June 6-7, 2011.
147. **Wu EQ**, Zhou S, Yu AP, Lu M, Graf T. Factors Associated With Insulin Therapy Discontinuation After Hospital Discharge in Patients With Type 2 Diabetes Initiated on Insulin During a Hospitalization. Poster presented at the ENDO 2011 Annual Meeting, Boston, MA, USA, June 4-7, 2011.

148. Yu AP, Namjoshi M, Xie J, Parikh K, **Wu EQ**, Guo A, Culver KW. Economic Evaluation of Denosumab Compared to Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. Poster presented at 2011 American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, June 3-7, 2011.
149. Erder MH, Xie J, Chen K, **Wu EQ**, Hodgkins P, Sikirica V. The Cost-Effectiveness of guanfacine Extended Release (GXR) versus Atomoxetine (ATX) for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, USA, May 21-25, 2011.
150. Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, **Wu EQ**. Health Care Resource Utilization and Economic Burden of Metastatic and Recurrent Locally-Advanced Head and Neck Cancer Patients. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, Maryland, USA, May 21-25, 2011.
151. Signorovitch J, Navarro R, Betts K, **Wu EQ**. Improved Indirect Treatment Comparisons for Comparative Effectiveness Research. Workshop at ISPOR 16th Annual International meeting, Baltimore, MD, USA, May 21-25, 2011.
152. Signorovitch J, Sawicki GS, Zhang J, Latremouille-Viau D, **Wu EQ**, von Wartburg M, Lizheng S. Use of Inhaled Tobramycin is associated with Reduced Mortality in Patients with Cystic Fibrosis. Poster presented at ISPOR 16th Annual International Meeting, Baltimore, MD, USA, May 21-25, 2011.
153. Alpert JS, Guérin A, Lin J, Jhaveri M, **Wu EQ**. Treatment Persistence Among Atrial Fibrillation/Atrial Flutter Patients on Combination Warfarin And Antiarrhythmic Drug Therapy in the Real-World Setting. Poster presented at American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC, USA, May 12-14, 2011.
154. Guérin A, Lin J, Jhaveri M, **Wu EQ**, Alpert J. Real-World Clinical Outcomes and Costs in Atrial Fibrillation/Flutter Patients on Combined Warfarin And Antiarrhythmic Drug Therapy. Poster presented at Academy of Managed Care Pharmacy 23rd Annual Meeting and Showcase, Minneapolis, MN, USA, April 27-29, 2011.
155. Alpert JS, Guérin A, Lin J, Jhaveri M, **Wu EQ**. Evaluation of International Normalized Ratio Monitoring and Anticoagulation Control In Atrial Fibrillation/Flutter Patients using Warfarin and Antiarrhythmic Drug Therapy. Poster presented at Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2011.
156. Papp K, **Wu EQ**, Goldblum OM, Gupta SR. AAD 2010: Fatigue Outcomes Following Withdrawal from and Retreatment with Adalimumab Among Patients Maintained on Adalimumab for Moderate to Severe Psoriasis. Poster presented at Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2011.
157. **Wu EQ**, Guérin A, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y. Resource Utilization and Costs associated with Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept in Patients with Psoriasis. Poster presented at Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2011.
158. **Wu EQ**, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y. Health Care Outcomes associated with Continuous use of Adalimumab versus Continuous and Intermittent use of Etanercept in Patients with Psoriasis. Poster presented at Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2011.

159. Guérin A , Bollu V, Guo A, Griffin JD, Yu AP, **Wu EQ**. Comparison of Adherence between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia. Poster presented at 2010 Annual Meeting of the American Society of Hematology, Orlando, FL, USA, December 4-7, 2010.
160. **Wu EQ**, Guérin A , Bollu V, Williams D, Guo A, Ponce de Leon D, Yu AP, Quintas-Cardama A. The Economic Burden of Pleural Effusions (PE) in Patients with Chronic Myeloid Leukemia (CML). Poster presented at 2010 Annual Meeting of the American Society of Hematology, Orlando, FL, December 4-7, 2010.
161. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Setyawan J, Dembiski M, Blum SI. Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple vs. Single Long-Acting Inhalers. Poster presented at American College of Chest Physicians CHEST 2010 Meeting, Vancouver, B.C., Canada, October 30-November 4, 2010.
162. Sawicki GS, Signorovitch J, Latremouille-Viau D, von Wartburg M, **Wu EQ**, Zhang J, Shi L. Use Of Inhaled Tobramycin is associated with Reduced Mortality in Patients with Cystic Fibrosis. Poster presented at 24th North American Cystic Fibrosis Conference, Baltimore, MD, USA, October 21-23, 2010.
163. Signorovitch J, Latrémouille-Viau D, Dea K, **Wu EQ**, Zhang J. Comparison of Drug Costs and Clinical Outcomes with Tobramycin Solution for Inhalation and Aztreonam Lysine for Inhalation in Cystic Fibrosis. Poster presented at 24th North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 21-23, 2010.
164. Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, **Wu EQ**. Persistence with Nebivolol Compared to Other  $\beta$ -Blockers in the Treatment of Hypertension: a Retrospective Claims Analysis. Poster presented at American Heart Association, High Blood Pressure Research Conference 2010 Scientific Sessions Washington, DC, USA, October 13-16, 2010.
165. Yim YM, Yu E, Yu AP, Yang H, **Wu EQ**. Healthcare Costs of Second-line (2L) Metastatic Colorectal Cancer (mCRC) Patients Treated with Bevacizumab (BV) versus Cetuximab (CX). Poster presented at 35th ESMO Congress, Milan, Italy, October 8-12, 2010.
166. Duffin KC, Guérin A , Yang H, **Wu EQ**, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM. Adalimumab Improves Sleep Symptoms in Patients with Psoriasis with Suboptimal Response to Etanercept, Methotrexate, or Phototherapy. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.
167. Kimball AB, Signorovitch J, Farooqui S, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Longer Disease Duration of Psoriasis with Hand/Foot Involvement is Independently associated with Persistent Impairment of Work Productivity and Activity. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.
168. Menter A, Signorovitch J, Parikh K, Yu AP, **Wu EQ**, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani P. ABT-874 Versus Etanercept or Placebo Treatment for Moderate to Severe Psoriasis: Health-Related Quality of Life. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.
169. Menter A, Guérin A, Yang H, **Wu EQ**, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM. Adalimumab Provides Health-Related Quality-of-Life Benefits for Patients with Psoriasis with Suboptimal Response to Etanercept Methotrexate, or Phototherapy. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.
170. Papp K, Guérin A , Parikh K, Signorovitch J, Yu AP, **Wu EQ**, Okun M, Gupta SR, Bao Y, PM. Benefit- Risk Analysis of Adalimumab for Patients with Psoriasis with Suboptimal Response to Etanercept, Methotrexate, or Phototherapy. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.

171. Papp K, Signorovitch J, Parikh K, Yu AP, **Wu EQ**, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P. Psoriasis Treatment with ABT-874: Effects on Health-Related Quality of Life and Work Productivity and Activity Impairment. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.
172. **Wu EQ**, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM. Resource Utilization and Costs in Patients with Moderate to Severe Psoriasis Treated with Adalimumab or Etanercept in a Real-World Setting. Poster presented at 19th Congress of the EADV - Gothenburg, Sweden, October 6-10, 2010.
173. **Wu EQ**, Guo A, Shi L, Lu M, Yu AP, Sharma H., Fan CPS, Vander Velde N. Comparing Early Intervention with Zoledronic Acid to No Bisphosphonate (BP) Therapy in Patients with Metastatic Prostate Cancer to Bone: A Study of the US Veterans Affairs (VA) Population. Poster presented at CABS 10th International Meeting, Sheffield, UK, September 22-25, 2010.
174. Bron M, Yu A, Marynchenko M, Sun SX, Yang H, **Wu EQ**. Total and Diabetes-Related Costs associated with Hypoglycemia in Type 2 Diabetes Mellitus Patients Initiated on Oral Antidiabetic Drugs from a Large U.S. Managed Care Cohort. Poster presented at ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, September 5-7, 2010.
175. **Wu EQ**, Yu DZ, Xie J, Gu RM. Selecting the Optimal Target Population for Formulary Coverage. Workshop at ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, September 5-7, 2010.
176. Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, **Wu EQ**. Blood Pressure Goal Achievement among Hypertension Patients Treated with Valsartan-Based Single Pill Combination vs. ARB-Based Free Combination in South Central Region. Poster presented at ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
177. Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CS, **Wu EQ**. Aliskiren Combined with Angiotensin II-Receptor Blockers (ARB) Resulted in Better Outcomes Compared to Arb Combined with Angiotensin-Converting Enzyme Inhibitors (ACEI): Results from a claims database analysis. Poster presented at ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
178. Guérin A, Bollu V, Guo A, **Wu EQ**, Yu AP, Sirulnik LA, Griffin JD. Non-Adherence to Imatinib In Chronic Myeloid Leukemia (CML) Patients is associated with Short- and Long-Term Negative Impacts on Health Care Resource Utilization and Costs. Poster presented at the ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
179. Guérin A, Bollu V, Guo A, **Wu EQ**, Yu AP, Sirulnik LA, Griffin JD. Non-Adherence to Imatinib in Chronic Myeloid Leukemia (CML) Patients is associated with Short- and Long-Term Negative Impacts on Healthcare Resource Utilization and Costs. Poster presented at the ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
180. Signorovitch J, **Wu EQ**, We LJ. Comparative Effectiveness Research for Personalized Medicine. Workshop at ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
181. Signorovitch J, Zhang J, **Wu EQ**, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH. Economic Impact of Switching from Valsartan to other Angiotensin II Receptor Blockers (ARBs) in Patients with Hypertension. Poster presented at ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.

182. **Wu EQ**, Bollu V, Guo A, Guérin A, Tsaneva M, Williams D, Griffin JD. Comparison of Healthcare Resource Utilization and Costs between Nilotinib and Dasatinib as Second Line Therapies in Chronic Myeloid Leukemia (CML). Poster presented at the ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
183. Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, **Wu EQ**, Bensimon AG, Fan CPS, Yu AP. Compliance and Health Care Utilization among Patients with Hypertension Treated with Single Pill vs. Free Combination Antihypertensive Therapy: U.S. National and State Level Results from a Claims Database Analysis. Poster presented at ISPOR 15th Annual International Meeting, Atlanta, GA, USA, May 15-19, 2010.
184. Yu A, Yang H, **Wu EQ**, Dembiski M, Blum S, Setyawan J. Economic Burden of Exacerbations in Chronic Obstructive Pulmonary Disease. Poster presented at ISPOR 15th Annual International Meeting, Atlanta, Georgia, USA, May 15-19, 2010.
185. Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, **Wu EQ**. Diabetes-Related Costs Associated with Hypoglycemia in Type 2 Diabetes Mellitus Patients Initiated on Oral Antidiabetic Drugs. Poster presented at Academy of Managed Care Pharmacy, 22nd Annual Meeting & Showcase San Diego, CA, USA, April 7-10, 2010.
186. **Wu EQ**, Signorovitch JE, Bao Y, Mulani PM. Comparative Effectiveness of Adalimumab versus Ustekinumab Treatment for Psoriasis: Clinical Efficacy, Safety and Cost per Responder. Poster presented at American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, FL, USA, March 5-9, 2010.
187. **Wu EQ**, Guérin A, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y. Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept. Poster presented at American Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2010.
188. **Wu EQ**, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y. Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis. Poster presented at American Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2010.
189. Remission of Major Depressive Disorder without Adverse Events: A Comparison of Escitalopram and Serotonin Norepinephrine Reuptake Inhibitors. Poster presented at U.S. Psychiatric & Mental Health Congress 2009, Las Vegas, NV, USA November 2-5, 2009.
190. **Wu EQ**, Signorovitch JE, Yu AP, Latremouille-Viau D, Zhang J, Dastani H, Kahler KH. Economic Impact of Switching from Valsartan to Other Angiotensin II Receptor Blockers (ARBs) in Patients with Hypertension. Poster presented at the AMCP 2009 Educational Conference, San Antonio, TX, USA, October 7 -9, 2009.
191. Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, **Wu EQ**, Erder H. The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression. Poster presented at the AMCP 2009 Educational Conference, San Antonio, TX, USA, October 7 -9, 2009.
192. Yu AP, Xie J, Bensimon A, Parikh K, **Wu EQ**, Ben-Hamadi R, Erder H. Economic Consequence of Switching to Citalopram after its Generic Entry Among Major Depressive Disorder (MDD) Patients Treated with Escitalopram. Poster presented at the AMCP 2009 Educational Conference, San Antonio, TX, USA, October 7 -9, 2009.
193. Increased Risk of Psychiatric Disorders in Young Patients with Crohn's Disease. Poster presented at Digestive Disease Week (DDW) Annual conference, Chicago IL, USA May 30-June 4, 2009.

194. Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's Disease. Poster presented at Digestive Disease Week (DDW) Annual conference, Chicago IL, USA May 30-June 4, 2009.
195. Guérin A, Guo A, Williams D, Yu AP, **Wu EQ**, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD. Treatment Patterns of Chronic Myelogenous Leukemia Patients who initiated their Treatment on Imatinib. Poster presented at American Society of Clinical Oncology Annual meeting 2009, Orlando, FL, USA, May 29-June 2, 2009.
196. Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsaneva M, Yu P, **Wu EQ**, Signorovitch J, Demetri GD. Real World Treatment Patterns of Gastrointestinal Stromal Tumor Patients. Poster presented at American Society of Clinical Oncology Annual meeting, Orlando, FL, USA, May 29- June 2, 2009
197. **Wu EQ**. Adverse Events Associated with Imatinib Dose Escalation versus Switching to Dasatinib in Patients with Chronic Myelogenous Leukemia. Poster presented at American Society of Clinical Oncology Annual meeting,, Orlando, FL, USA, May 29- June 2, 2009
198. Johnson S, Kaltenboeck A, Horn C, **Wu EQ**, Majethia S, Mulani P, Chao J. Number-Needed-to-Treat (NNT) Analysis: Remission Rates for adalimumab vs. Infliximab in Crohn's Disease. Poster presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
199. Lauzon V, Kaltenboeck A, Yu A, Ramakrishnan K, Marynchenko M, **Wu EQ**, Ben-Hamadi R, Erder M, Bose A. The Economic Impact of Generic Switching For Patients with Major Depressive Disorder (MDD) Treated With Escitalopram Or A Patented SSRI. Poster presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
200. Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, **Wu EQ**, Ben-Hamadi R, Erder MH, Bose A. Economic Assessment of Second-line Treatment: Switching from a Generic SSRI to Escitalopram, an SNRI, or Another Generic SSRI for Patients with Major Depressive Disorder (MDD). Poster presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
201. **Wu EQ**, Signorovitch, J, Yu A, Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data. Workshop presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
202. **Wu EQ**, Cahill K, Bieri C, Ben-Hamadi R, Yu A, Erder M. Comparison of Hospitalizations and Health Care Costs of Elderly Major Depressive Disorder (MDD) Patients Treated With Escitalopram, Generic SSRIs, Or SNRIs. Poster presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
203. Yu AP, Guo A, Guérin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, **Wu EQ**. Healthcare Resource Utilization Associated with Escalating Imatinib versus Switching to Dasatinib in Patients with Chronic Myelogenous Leukemia. Poster presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
204. Yu A, Bensimon A, **Wu EQ**, Ben-Hamadi R, Bourezak A, Erder M. Economic Implication of Dose Escalation in Depressed Patients Treated with Escitalopram or Venlafaxine XR. Poster presented at ISPOR 14th Annual International Conference, Orlando, FL, USA, May 16-20, 2009.
205. Kimball AB, **Wu EQ**, Mulani P, Gupta S. Adalimumab's Benefits for Patient-Reported Outcomes in Psoriasis Patients Are Consistent Across Subgroups With Different Disease Histories. Poster presented at American Academy of Dermatology Annual meeting, San Francisco, CA, USA, March 6-10, 2009.

206. Menter A, **Wu EQ**, Mulani, P, Gupta S. Discontinuation of Adalimumab Treatment for Psoriasis Following Sustained Response: Effects on Health-Related Quality of Life. Poster presented at American Academy of Dermatology Annual meeting, San Francisco, CA, USA, March 6-10, 2009.
207. Young Patients with Crohn's Disease Are at Increased Risk for Psychiatric Disorders. Poster presented at European Crohn's & Colitis Organisation 4th Congress, Hamburg, Germany, February 5-7, 2009.
208. Loftus E, Feagan B, Colombel JF, **Wu EQ**, Yu A, Chao J, Mulani P. Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist-Naïve Patients with Crohn's Disease. Poster presented at American College of Gastroenterology 2008 Annual meeting, Orlando, FL, USA, October 3-8, 2008.
209. Rubin D, Rutgeerts P, Colombel JF, **Wu EQ**, Yu A, Chao J, Mulani P. Health-Related Quality Of Life in TNF-Antagonist-Naïve Patients with Crohn's Disease during Short- and Long-Term Adalimumab Treatment. Poster presented at American College of Gastroenterology 2008 Annual meeting, Orlando, FL, USA, October 3-8, 2008.
210. Plevy S, **Wu EQ**, Yu A, Chao, J, Mulani P. Infliximab Dosage-Increase Rate in Patients with Crohn's Disease. Poster presented at American College of Gastroenterology 2008 Annual meeting, Orlando, FL, USA, October 3-8, 2008.
211. Erder MH, **Wu EQ**, Lu M, Ben-Hamadi R, Beaulieu N. Treatment Compliance and Health Care Costs of Medicaid Depressed Adult Patients Treated with Escitalopram versus Citalopram Poster presented at ECNP 21st Congress, Barcelona, Spain, August 30-September 3, 2008.
212. Pandya BJ, Yu A, **Wu EQ**, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW. Achieving Glycemic Goal with Initial Combination Therapy Versus Sequential Augmentation Therapy using Metformin and Pioglitazone. Poster presented at 44th EASD meeting, Rome, Italy September 7-11, 2008.
213. Health Care Utilization and Costs of Depressed Patients Treated with Escitalopram versus SNRIs. Poster presented at ECNP 21st Congress, Barcelona, Spain, August 30-September 3, 2008.
214. Impact of Switching to Another SSRI for Non-Medical Reasons on Health Care Utilization and Costs Among MDD Patients Initiated with Escitalopram. Poster presented at APA, Boston, MA, USA, August 14-17, 2008.
215. **Wu EQ**, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW. Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies. Poster presented at American Diabetes Association's 68th Scientific Sessions, San Francisco, CA, USA, June, 6-10, 2008.
216. Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? - A Community-Based US Survey Study. Poster presented at Digestive Disease Week, San Diego, CA, USA, May 17-22, 2008.
217. Nighttime Symptoms and Sleep Impairment among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs). Poster presented at Digestive Disease Week, San Diego, CA, USA, May 17-22, 2008.
218. Kane S, **Wu EQ**, Chen L, Yu A, Tsaneva M, Chao J, Mulani P. Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn's Disease. Poster presented at ISPOR 13th Annual International Meeting, Toronto, Canada, May 3-7, 2008.

219. **Wu EQ**, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A. Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI. Poster presented at ISPOR 13th Annual International Meeting, Toronto, Canada, May 3-7, 2008.
220. Yu A, **Wu EQ**, Perrson B, Chang J, Costales C, Gricar J. Clinical and Economic Outcomes among Women Using Levonorgestrel-Releasing Intrauterine System (LNG-IUS). Podium presentation at ISPOR 13th Annual International Meeting, Toronto, Canada, May 3-7, 2008.
221. Stress Single-Photon Emission Computed Tomography Reduces Total Direct Medical Costs and Rates of Utilization After Acute Myocardial Infarction. Poster presented at American College of Cardiology (ACC) 57th Annual Scientific Session, Chicago, IL, USA, March 29-April -1, 2008.
222. Navarro R, **Wu EQ**. Health Economics Impact in the Treatment of Depression. National Association of Managed Care Physicians (NAMCP), 2007.
223. **Wu EQ**, Greenberg P, Erder MH. Assessing Step Therapy/Generic Switching: Clinical and Economic implications of Acquisition Costs vs. Total Health Care Costs Paradigm, Congressional Budget Office, 2007
224. Colombel JF, **Wu EQ**, Yu AP. Impact of adalimumab (HUMIRA (R)) on Patient-Reported Outcomes among Patients with Fistulizing Crohn's Disease in the CHARM Trial. Poster presented at American College of Gastroenterology (ACG), Philadelphia, PA, USA, October 12-17, 2007.
225. Colombel JF, Sandborn WJ, Rutgeerts P, Yu A, **Wu EQ**, Pollack PF, Chao J, Mulani P. Continuous vs. Induction Only/Reinitiated Adalimumab Maintenance Therapy Yields Optimal Results for Moderate to Severe Crohn's Disease: Sub-analysis of CHARM. Poster presented at American College of Gastroenterology (ACG), Philadelphia, PA, USA, October 12-17, 2007.
226. Loftus EV, **Wu EQ**, Yu AP. Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes. Poster presented at American College of Gastroenterology (ACG), Philadelphia, PA, USA, October 12-17, 2007.
227. Nelson SP, Kothari S, **Wu EQ**, Persson B, Beaulieu N, Arana M, Lu M. Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens. Poster presented at American College of Gastroenterology (ACG), Philadelphia, PA, USA, October 12-17, 2007.
228. Nelson SP, Kothari S, **Wu EQ**, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H. Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study. Poster presented at American College of Gastroenterology (ACG), Philadelphia, PA, USA, October 12-17, 2007.
229. Birnbaum H, Greenberg P, Tang J, Hsieh M, **Wu EQ**, Reygrobellet C, Ben-Hamadi R. Antidepressant Treatment Patterns and Related Costs among U.S. Employees. Poster presented Institute on Psychiatric Services (APA-I.), New Orleans, LA, USA, October 11-14, 2007.
230. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram,. Poster presented Institute on Psychiatric Services (APA-I.), New Orleans, LA, USA, October 11-14, 2007.

231. **Wu EQ**, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ. Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay. Poster presented American Society of Nuclear Cardiology (ASNC), San Diego, CA, USA, September 6-9, 2007.
232. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram. Poster presented at International Health Economics Association, Copenhagen, Denmark, July 8-11, 2007.
233. **Wu EQ**, Elaine Y, Greenberg P, Erder M.H., Yu A, Buessing M. Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIS. Poster presented at New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, USA, June 13-16, 2007.
234. **Wu EQ**, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J. Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients, Poster presented at ASCO Annual Meeting., Chicago, IL, USA, June 1-5, 2007.
235. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, **Wu EQ**, Mulani PM. An Evaluation of Adalimumab on the Risk of Hospitalization in Patients with Crohn's Disease, Data from CHARM. Poster presented at Digestive Disease Week, Washington, DC, USA, May 19-24, 2007.
236. **Wu EQ**, Yang E, Greenberg P, Erder MH, Yu A, Buessing M. Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI). Poster presented at ISPOR 12th International Meeting, Arlington, VA, USA, May 19-23, 2007.
237. **Wu EQ**, Yang E, Greenberg P, Erder MH, Yu A, Buessing M. Comparison of Health Care Costs and Hospitalization Days of Elderly Major Depressive Disorder Patients Treated with Escitalopram and Other Antidepressants. Poster presented at ISPOR 12th International Meeting, Arlington, VA, USA, May 19-23, 2007.
238. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparison of Health Care Costs and Hospitalization Days of Elderly Major Depressive Disorder Patients Treated with Escitalopram and Other Antidepressants. Poster presented at ISPOR 12th International Meeting, Arlington, VA, USA, May 19-23, 2007.
239. **Wu EQ**, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM. Lower Disease Activity And Clinical Remission Are Associated With Reduced Hospitalization Risk In Crohn's Disease. Poster presented at ISPOR 12th International Meeting, Arlington, VA, USA, May 19-23, 2007.
240. **Wu EQ**, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R. Healthcare Cost of Gout in an Elderly Population: A Claims Database Analysis. Poster presented at American Geriatrics Society Annual Scientific Meeting, Seattle, WA, USA, May 2-6, 2007.
241. **Wu EQ**, Patel P, Krishnan E, Yu AP. Treatment Cost of Gout in an Elderly Population: A Claims Database Analysis. Poster presented at American Geriatrics Society Annual Scientific Meeting, Seattle, WA, USA, May 2-6, 2007.
242. **Wu EQ**, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R. Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter? Poster presented at American Geriatrics Society Annual Scientific Meeting, Seattle, WA, USA, May 2-6, 2007.

243. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram. Poster presented at European College of Neuropsychopharmacology (ECNP) Regional Meeting, Sofia, Bulgaria, April 27-29, 2007.
244. **Wu EQ**, Mody R, Krishnan E, Yu AP, Cahill K, Tang J, Patel P. Tighter Control of Serum Uric Acid in Gout is Associated with Lower Morbidity and Health Care Costs, November, 2006.
245. **Wu EQ**, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P. Loss of Treatment Response among Crohn's Disease Patients Receiving Infliximab Maintenance Therapy, Academy of Managed Care Pharmacy, 2006.
246. **Wu EQ**, Borton J, Kahn E, Said G, T.K. Le, Garcia-Cebrian A, Monz B. Prevalence of Diabetic Peripheral Neuropathy and Associated Pain in French Adults, European Neurological Society, 2006.
247. **Wu EQ**, Birnbaum H, Zhang HF, Radeva R, Yang E, Castor A. Medical Costs and Hospitalization of Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder Who Received Alternative Therapies, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
248. **Wu EQ**, Xie J, Sullivan PW. Adult Economic Status and Obesity in the United States: 2000-2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
249. **Wu EQ**, Xie J, Hill JO, Wyatt H, Sullivan PW. Obesity and Quality of Life in the United States: 2000-2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
250. **Wu EQ**, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to the EQ-5d Health Utility in Metastatic Hormone-Refractory Prostate Cancer Patients, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
251. **Wu EQ**, Birnbaum H, Ben-Hamadi R, Yu A, Tang J, Greenberg P, Gilloteau I, Smadja E. Annual Costs Associated with Patterns of Antidepressant Treatment Response among Employees, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
252. **Wu EQ**, Yu AP, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M, Yang E. Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes, American Diabetes Association (ADA), 2006.
253. Yu AP, **Wu EQ**, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M. Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients, American Diabetes Association (ADA), 2006.
254. **Wu EQ**, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E. Patterns of Antidepressant Treatment Response in an Employed Population, American Psychiatric Association (APA) Annual Meeting, 2006.
255. **Wu EQ**, Birnbaum H, Zhang HF, MD, Radeva J, Yang E, Castor A. Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies, American Psychiatric Association (APA), 2006.
256. Colice G, Crivera C, **Wu EQ**, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST. Inpatient and Emergency Department Utilization of Persistent Asthma Patients, American Thoracic Society (ATS), 2006.

257. **Wu EQ**, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE. Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective. The American College of Obstetricians and Gynecologists (ACOG), 2006.
258. Hartmann KE, Birnbaum H, **Wu EQ**, Ben-Hamadi R, Spalding J, Stang P. Annual Costs Associated with Diagnosis of Uterine Fibroids. The American College of Obstetricians and Gynecologists (ACOG), 2006.
259. Cremieux P, Xie J, **Wu EQ**, Castor A. Health-Related Quality Of Life of Anemia Patients in the U.S., International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
260. Cremieux P, Xie J, Greenberg P, **Wu EQ**, Castor A. Obesity's Impact on Diabetes Patients' Health-Related Quality Of Life In The U.S., International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
261. Xie J, **Wu EQ**, Zheng ZJ, Croft JB, Mensah GA, Labarthe D. Health-Related Quality Of Life of Stroke Survivors in the U.S., International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
262. **Wu EQ**, Xie J, Hill JO, Wyatt H, Sullivan PW. Quality of Life of Obese Adults in the US, International Society for Quality of Life Research (ISOQOL), 2005.
263. Sullivan PW, Ghushchyan V, **Wu EQ**. Systematic Differences in Subjective vs. Societal Preferences, International Society for Quality of Life Research (ISOQOL), 2005.
264. **Wu EQ**, Xie J, Sullivan PW. Employment and Income Associated with Obesity and Overweight in the US, North American Association for the Study of Obesity (NAASO), 2005.
265. Colice G, Crivera C, Varghese S, Faruqi R, **Wu EQ**, Birnbaum H, Daher M, Marynchenko MB. Healthcare Costs of Patients with Persistent Asthma, Academy of Managed Care Pharmacy (AMCP), 2005.
266. Rousculp MD, Sasser AC, Birnbaum HG, Moyneur E, **Wu EQ**, Mallet D, Marcus R. Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy, Academy of Managed Care Pharmacy (AMCP), 2005.
267. **Wu EQ**, Birnbaum H, Cifaldi M, Kang Y, Colice GL. Acute Exacerbation of Chronic Bronchitis (AECB) Treatment Effectiveness: Comparison of Macrolides to Fluoroquinolones, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
268. **Wu EQ**, Birnbaum HG, Aggarwal J, Moulis M. The Economic Burden of Schizophrenia in the United States in 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2005.
269. **Wu EQ**, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. Using Claims Data to Estimate the Annual Prevalence of Schizophrenia in the United States, 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2005.
270. **Wu EQ**, Birnbaum H, Parece A, Kang Y, Mareva MN, Taitel H. Interstitial Cystitis Costs. Treatment and Comorbidities in an Employed Population, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
271. **Wu EQ**, Birnbaum H, Kessler R, Shi L, Ball D. Economic Burden of Lost Productivity due to Schizophrenia in the United States: 2002, American Psychiatric Association (APA), 2005.

272. Ronald KC, Birnbaum H, Demler O, Falloon L, Gaggon E, Guyer M, Howes M, Kendler KS, Shi L, **Wu EQ**, Walters E. Prevalence and Correlates of Nonaffective Psychosis: Results from NCS-R, Society of Biological Psychiatry (SOBP), 2005.
273. **Wu EQ**, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J. Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
274. **Wu EQ**, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L. Direct Health Care Costs of Schizophrenia in the United States: 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
275. **Wu EQ**, Birnbaum H, Aggarwal J, Moulis M. Estimating Annual US Prevalence Rate of Schizophrenia in 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
276. Sasser A, Rousculp MD, Birnbaum H, Moyneur E, **Wu EQ**. Using A Budget Impact Model to Predict First-Year Use of a new Osteoporosis Therapy, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
277. **Wu EQ**, Birnbaum H, Cifaldi M, Colice G, Kang Y. Development of a COPD Severity Score in ClaimsDatabase, International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2004.
278. **Wu EQ**, Birnbaum H, Greenberg P, Huang Z, Kessler R, Parece A, Victor T. Drug Treatment Patterns of Bipolar Disorder and Associated Costs, National Institute of Mental Health's (NIMH) New Clinical Drug Evaluation Unit (NCDEU) meeting, 2004.
279. **Wu EQ**, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R. Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Perspective, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
280. Parece A, **Wu EQ**, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC. Comorbidities and Cost Associated with Bipolar Disorder, American Public Health Association's (APHA), 2004.
281. **Wu EQ**, Howard BG, Mareva MN. Cost and Comorbidities Associated with Atrial Fibrillation, NASPE - Heart Rhythm Society, 2004.
282. **Wu EQ**, Birnbaum HG, Milena M. Cost and Comorbidities Associated with Atrial Fibrillation by Different Age Groups, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
283. Parece A, **Wu EQ**, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC. Cost and Comorbidities Associated with Bipolar Disorder, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
284. **Wu EQ**, Birnbaum HG, Greenberg P, Kessler RC, Huang Z, Victor T. Drug Treatment Patterns of Bipolar Disorder and Associated Costs, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
285. **Wu EQ**, Johnson KA, Nichol MB. Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.

286. **Wu EQ**, Johnson KA, Nichol MB. Instrument Strength and Performance of a Parametric Latent Index Model in Estimating Average Treatment Effect (ATE), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
287. **Wu EQ**, Nichol MB, Johnson KA. Performance of Two Conditional Expectation Methods under Unobserved Selection Bias, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
288. Chaikledkaew U, **Wu EQ**, Johnson KA. A Methodology to Identify High-Risk Patients With Diabetes In The California Medicaid Population (Medi-Cal), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
289. Chaikledkaew U, **Wu EQ**, Johnson KA. Factors Associated With High-Risk Diabetic Patients In The California Medicaid Populations (Medi-Cal), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
290. Rosberg J, Oster EF, **Wu EQ**, Fastenau J, Piech CT. Dose Conversion Of Erythropoietic Agents In Chemotherapy-Induced Anemia: A Meta-Analysis, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
291. Barlev A, Globe D, **Wu EQ**, Yu W, Johnson K. "The Comparison of Different Methods for Determining The Impact of Migraine Prophylaxis on Costs," 2003, International Society for Pharmacoeconomics and Outcome Research (ISPOR) 8th Annual International Meeting.
292. **Wu EQ**, Hay J. Survival and Nursing Home Free Survival (NHFS) of Alzheimer's Disease (AD) Patients, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2001.
293. **Wu EQ**, Hay J. Alternative Management Strategies for Dyspepsia, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2001.
294. **Wu EQ**, Hay JW. Comparative Econometric Models of Medical Costs, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2000.
295. Burk C, Nichol MB, **Wu EQ**, Gilderman A, Salas J. The Impact of an Over-the-Counter Migraine Medication on Quality of Life, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2000.

***Advisory Board Positions and Professional Association Memberships***

- 2012-2014 Co-Editor, *PharmacoEconomics*, Health Economic Issues in China
- 2013- Member, American Society of Clinical Oncology
- 2012- Deputy Director of the Health Economics and Policy Research Center of TJAB, China
- 2009- Expert Panel, China Health Economic Evaluation Center, Chinese Medical Doctor Association
- 2009- Adjunct Professor, Nankai University, School of Pharmacy, China
- 2009- Advisory Board, Tianjin Technology and Development Center, China
- 2007 Advisory Board, Daiichi Sankyo Inc.
- 2005-06 Member, Society of Industry Leaders (SIL)

- 2003- Member, Chinese Economists Society (CES)
- 2002-03 Member, International AIDS Society (IAS)
- 2002 Member, Drug Information Association (DIA)
- 2001- Member, International Society of Pharmacoeconomics and Outcome Research (ISPOR)